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Abstract 
The functions of a large number (> 435) of extracellular regulatory proteins are 
controlled by their interactions with heparan sulfate (HS). In the case of fibroblast 
growth factors (FGFs), HS binding controls their transport between cells and is 
required for the assembly of a high affinity signaling complex with the cognate FGF 
receptor. However, the specificity of the interaction of FGFs with HS is still debated. 
In this thesis, a panel of FGFs (FGF-1, FGF-2, FGF-7, FGF-9, FGF-18 and FGF-21) 
spanning five FGF sub-families were used to probe their specificities for HS/heparin 
at different levels: recombinant FGF proteins were expressed and purified and their 
biological activities tested in a DNA synthesis assay. Then, the proteins were tested 
for their heparin binding specificity using a variety of complementary approaches: 1. 
Measurement of the binding parameters of FGFs and a model heparin sugar in an 
optical biosensor or by microscale thermophoresis; 2. Identification of the heparin 
binding site (HBS) in the proteins using a Protect and Label strategy; 3. 
Determination of stability changes in FGFs when bound to different heparin sugars 
and related glycosaminoglycans employing differential scanning flurometry; 4. 
Measurement of the conformational changes in FGFs when binding to a variety of 
molar ratios of heparin and chemically modified heparins using synchrotron radiation 
circular dichroism (SRCD); 5. Measure directly the binding of FGF-2 to cellular HS 
using nanoparticles (NPs) to label the FGF-2 and transmission electron microscopy. 
For interaction with heparin, the FGFs have KDs varying between 38 nM (FGF-18) 
and 620 nM (FGF-9) and association rate constants spanning over 20-fold (FGF-1, 
2,900,000 M
-1
s
-1
, FGF-9, 130,000 M
-1
s
-1
). The canonical HBS in FGF-1, FGF-2, 
FGF-7, FGF-9 and FGF-18 differs in its size and these FGFs have a different 
complement of secondary HBS, ranging from none (FGF-9) to two (FGF-1). 
  
Differential scanning fluorimetry identified clear preferences in these FGFs for 
distinct structural features in the polysaccharide. SRCD revealed conformational 
changes in FGFs induced by binding to heparin and the changes were distinct at 
different heparin concentrations. Moreover, there was evidence that the 
conformational changes of FGFs differed with chemically modified heparins, 
indicating that the conformational change caused by binding to heparin is related to 
the sulfation pattern. At the cellular level, FGF-2 labeled with nanoparticles allowed 
the distribution of FGF-2 to be determined in the pericellular matrix of Rama 27 
fibroblasts. The results showed that the FGF-2-NPs were specifically bound to 
cellular HS and were clustered. Taken together, these data suggest that the 
differences in heparin binding sites in both the protein and the sugar are greatest 
between FGF sub-families and may be more restricted within a FGF sub-family in 
accord with the known conservation of function within FGF sub-families, which 
supports the idea that heparin binding of these proteins is specific, but in terms of 
consensus sites on the GAG chain, rather than precisely defined chemical structures. 
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Chapter 1 General Introduction 
1.1 Overview 
Fibroblast growth factors (FGFs) and their receptors comprise an integrated signaling system 
in multicellular organisms. These systems allow the continual exchange of information 
between cells and their internal and external environments in the developing embryo and 
adult organisms [1]. The archetypal FGFs, basic fibroblast growth factor (bFGF now FGF-2) 
and acidic fibroblast growth factor (aFGF now FGF-1) were first isolated from pituitary and 
brain [2-6]. Thereafter, the genes for FGF-1 and FGF-2 were found to be widely expressed in 
adult tissues and in the developing embryo. FGFs possess two types of receptors, heparan 
sulfate (HS) and tyrosine kinases (FGFR), which are involved in transducing the FGF signal 
into the cell [7]. Twenty-two fgf genes and five fgfr genes have been identified so far in 
human and mouse, fgf1-23 and fgfr1-5; human fgf15 and mouse fgf19 have not been 
identified. They may have been lost or diverged during gene evolution.  
1.2 Evolution of FGFs 
fgf genes have not been identified in unicellular organisms, by contrast, they have been 
identified in multicelluar organism: two  fgf genes and one fgfr gene have been identified in 
C.elegans, however, twenty two fgf genes and five fgfr genes have been identified in human 
and mouse, and the zebra fish fgf gene family has twenty seven members [1]. This indicates 
that the fgf gene family expanded greatly during the evolution of primitive metazoa to 
vertebrates [8]. Over the course of evolution, the fgf gene family has expanded in two phases. 
In the first phase, during early metazoan evolution, fgf genes expanded more than once, from 
two or three to six genes by gene duplication. In the second phase, during the evolution of 
early vertebrates, the FGF family expanded via two large-scale genome duplications to result 
in two to four members in each of the seven sub-families of FGFs [8] (Figure 1.1).  
However, the detailed history of their expansion and the reasons that they  form such a large 
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family is still uncertain, because the functional differences between different FGFs are not 
always apparent [7, 8].  
1.3 FGF sub-families 
By phylogenetic analysis, the 22 human FGFs can be divided into 7 sub-families: FGF-1, 
FGF-4, FGF-7, FGF-8, FGF-9, FGF-11 and FGF-19, with each sub-family containing 2 to 4 
different FGFs (Figure 1.1 and Table 1.1). 
 
 
 General Introduction 
 
3 
 
 
Figure 1.1 Evolutionary tree of the FGF family. 
The protein sequences of 22 human FGFs were aligned using Cluster X software and the tree 
was constructed by automatic likelihood method. 
1.4 FGF gene structure and localization 
1.4.1 Gene localization 
Following the sequencing of the human genome, the 22 human fgf gene locations are all 
known. These 22 human FGFs comprise ~150-300 amino acids and have a conserved core 
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structure containing about 120 amino acids with ~30-60 % identity [1, 9]. Although, FGFs 
share similar amino acid sequences, most of the genes have different localizations in humans 
(Table 1.1), e. g., fgf-2 is located on human chromosome 4 [10] and fgf-1 is located on 
chromosome 5, between bands 5q 31.3 and 5q 33.2 [10]. If other members in other sub-
families are compared, there seems little relation between them, e.g. in the FGF-4 sub-family, 
FGF-4 is located in human chromosome 11, however, the FGF-5 gene is located in 
chromosome 4 and FGF-6 in chromosome 12 (Table 1.1). 
1.4.2 Gene structure 
FGF gene structure dictates protein structure. FGF genes contain 2-5 different exons to form 
mRNA, which are separated by 1-4 large introns, e.g., in fgf-2 gene structure, three exons  
are separated by two relatively large introns [11]. Within sub-familes FGFs have similar 
numbers of exons and introns, e.g., all fgf-4, fgf-8, fgf-9 and fgf-11 sub-family members have 
the same exon and intron numbers in each sub-family.  
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 fgfs Localization Exons Introns Total gene length 
fgf-1 sub-family fgf-1 5q31 4 3 125.88 kb 
 fgf-2 4q26-27 3 2 91.53 kb 
fgf-4 sub-family fgf-4 11q13.3 3 2 22.38 kb 
 fgf-5 4q21 3 2 90.08 kb 
 fgf-6 12p13 3 2 37.46 kb 
fgf-7 sub-family fgf-3 11q13 3 2 28.8 kb 
 fgf-7 15q15-21.1 4 3 454.05 kb 
 fgf-10 5p12-p13 3 2 106.16 kb 
 fgf-22 19p13.3 3 2 23.78 kb 
fgf-8 sub-family fgf-8 10q24 5 4 25.75 kb 
 fgf-17 8q21 5 4 26.41 kb 
 fgf-18 5q34 5 4 57.97 kb 
fgf-9 sub-family fgf-19 11q13.1 3 2 26.41 kb 
 fgf-21 19q13.1-qter 3 2 22.24 kb 
 fgf-23 12p13.3 3 2 31.50 kb 
fgf-19 sub-family fgf-9 13q11-q12 3 2 53.12 kb 
 fgf-16 Xq13 2 1 23.12 kb 
 fgf-20 8p21.3-p22 3 2 30.01 kb 
fgf-11 sub-family fgf-11 17q13.1 5 4 27.69 kb 
 fgf-12 3q28 5 4 645.87 kb 
 fgf-13 Xq26.3 5 4 611.21 kb 
 fgf-14 13q34 5 4 699.09 kb 
 
Table 1.1 Human fgf location  
Twenty two human gene locations on different chromosomes, numbers of exons, numbers of 
introns and total gene lengths (data from Ornitz et al. 2001 and Ensembl database, 
(Cambridge, UK. http://www.ensembl.org/index.html) [12]. 
1.4.3 FGF secretion 
Except for FGF-1, FGF-2, FGF-9, FGF-11-15, FGF-20 and FGF-22, all other FGFs  have  
classic cleavable N-terminal signal peptides and are secreted from cells via the endoplasmic 
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reticulum/Golgi pathway [1]. Although, FGF-9, FGF-16 and FGF-20 lack cleavable N-
terminal signal peptides, they are still secreted through this pathway [1]. FGF-1 and FGF-2 
do not have signal peptides and can be released from damaged cells or by an exocytotic 
mechanism that is independent of the endoplasmic-reticulum-Golgi pathway [13]. FGF-11, 
FGF-12, FGF-13 and FGF-14 do not have signal sequences and are thought to remain 
intracellular.  
1.4.4 Alternative splicing 
fgf genes contain 2-5 coding exons, the size of the coding portion of the genes ranges from 
under 5 kb (in fgf-3 and fgf-4) to more than 100 kb (in fgf-12) [12]. In fgf-1 and fgf-2 the 
position of the boundaries between introns and exons are similar [14]. Exon 1 of fgf usually 
contains the initiation methionine, except in fgf-2 and fgf-3, which have additional 5’ 
transcribed sequences that initiate from upstream CUG codons [12, 15, 16]. 
The total lengths of most of fgfs are between 22 to 126 kb (Table 1.1). However, fgf-7 is 
454.05 kb and three FGF-11 subfamily members also have large genes (fgf-12, 645.87 kb; 
fgf-13, 611.21 kb;  fgf-14, 699.09 kb). 
In several fgf sub-families, there are other similarities: exon 1 can be divided into 2-4 
alternatively spliced sub-exons, e.g., fgf-8, sub-exon 1A-1D, in which an initial codon (ATG) 
in sub-exon 1A is used to start coding [12]. The organization of fgf is conserved in mouse, 
zebrafish and humans, however, its functional significance is not understood [12]. In some 
other cases, such as the fgf-11 sub-family, there exist alternative amino termini, because of 
alternative 5’ exons. However, whether a common 5’ untranslated exon splices to exons in 
these sub-families, or an alternative promoter and regulatory sequences are active, remains 
uncertain [12]. 
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1.5 FGF ligand structure 
1.5.1 Core structure of FGFs 
The FGF family exhibits a folding pattern similar to the cytokine interleukin-1β, as first 
revealed by X-ray crystallography of FGF-2 [17]. The overall structure of the core of FGF-2 
is a cylindrical barrel made up of 12 anti-parallel β-strands. The backbone of the structure 
can be described as a pyramid, where the three sides are built of two β-strands together 
forming a β-sheet barrel of six anti-parallel strands (Figure 1.2). The base of the pyramid is 
built of six additional, β-strands extending from the three sides of the pyramid to close one 
end of the barrel [17]. The core structure of the FGF family also includes the regions of the 
molecules that are required for binding to FGFR and HS [18]. 
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Figure 1.2 FGF-2 3-dimensional structure ribbon diagram. 
Crystal structure of FGF-2 (PDB: 2FGF [18], residues 28-153) is shown using a ribbon 
diagram. The structure was rendered with SPDBV and exported using PRO-RAY 
(Persistence of Vision Ray tracer Pty. Ltd. Victoria, Australia, http://www.povray.org/). 
  
N-terminus 
β1 
β12 
β2 
β3 
β8 
β4 
β9 
β5 
β11 
β7 
β6 
β10 
 General Introduction 
 
9 
 
1.5.2 The structural similarities and differences of the FGF ligands 
The core structures of FGFs are quite similar according to the known 3-D structures of FGFs 
and sequence alignment, so, therefore, the main differences are due to the lengths of loops, 
the amino acid side chains and the N- and C-termini, which are not part of the core structure. 
The crystal structure of FGF-9 (PDB: 1IHK) [19] indicates that the main difference between 
FGF-9 and FGF-1 subfamily members are the loops between β stand 1-2 and 9-10 [20]. 
Loop 1-2 of FGF-9 is one amino acid shorter than loop 1-2 of FGF-1 and FGF-2, however, 
loop 9-10 is 6 residues longer than the corresponding loop in FGF-2 and 4 residues more 
than the one in FGF-1 [20]. Because of the longer sequence, loop 9-10 bulges out from the 
main structure of FGF-9 [20]. Another difference between the structures of these FGFs is the 
conformational differences in N- and C-termini. The two termini in the FGF-1 sub-family 
are disordered in crystal structures to the extent that these proteins are expressed as truncated 
variants in order to obtain crystals. In contrast, in FGF-9, the N-terminal contains an α helix 
and the C-terminal of FGF-9 (17 amino acids), which is much longer than that of FGF-1 (4 
amino acids) and FGF-2 (3 amino acids) also contains a short helical structure [20]. 
In the FGF-7 subfamily, FGF-7 and FGF-10 have a longer β1 strand than FGF-1 and FGF-2, 
[21-23]. Also, FGF-7 and FGF-10 have a single hydrogen bond between the β10 and β11 
strands to link them, which is different from other FGFs [23]. The consequent 
conformational restrictions may be a hallmark of the FGF-7 sub-family [23]. Like FGF-9, 
FGF-7 and FGF-10 were also reported to be much longer at loop β1-2 and β9-10 compared 
to FGF-1 and FGF-2 [23].  
FGF-8 has a larger N-terminus compared to other FGFs, which contains an α helix and some 
disordered sequence, and so has a very different structure from the N-termini of other FGFs, 
It is predicted that FGF-17 and FGF-18 may also have similar N-termini [24]. 
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The 3-D structures of FGFs determined by crystallography are quite similar to the NMR 
derived models, but they are not exactly the same. For example, the FGF-1 crystal structure 
(PDB: 2AFG) [25] has a shorter β1 (LLYC) and β12 (LPL) than the corresponding NMR 
structure (PBD: 2ERM [26], β1: KPKLLYCS, β12: LFLPLPVS). This indicates that the 
FGF solution structures may differ from the crystal structures. Taken together, the main 
differences between these FGF structures are the loop regions, and also the N- and C- 
termini. Alongside, there are differences in amino acid sequence, which do not affect the 
overall structure. It is proposed that these differences are the reasons for FGFs having 
distinctive receptor binding specificities, allowing FGFs to activate distinct signaling 
pathways. 
1.6 Heparin/HS structure 
1.6.1 Heparin/HS disaccharide structure 
Heparin is found in vivo in mast cells; HS is found at the cell surface and in ECM of most 
cells [27]. Heparin and HS together, hyaluronic acid (HA), chondroitin sulphate (CS), 
dermatan sulfate (DS) and keratan sulfate all belong to the family of glycosaminoglycans 
(GAG), which are long unbranched polysaccharides. HS and heparin have the same 
repeating disaccharide architecture composed of a uronic acid, α-L-iduronic or β-D-
glucuronic and D-glucosamine (Figure. 1.3) [28]. The initial product of biosynthesis is a 
repeating disaccharide of glucuronic acid and N-acetyl glucosamine of 50 to 300 
disaccharides. This is then modified, initially by N-deacetylase / N-sulfotransferase activity, 
which replaces the N-acetyl group of glucosamines with a N-sulfate. This modification is 
clustered along the chain and acts as a marker for the other modifications: epimerization of 
glucuronic acid to iduronic acid, O-sulfation of C2 on iduronic acid and of C6 and C3 of 
glucosamine [29].  
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Figure 1.3 Heparin/HS repeating disaccharides unit. 
The repeating disaccharide unit contains two parts: a L-iduronic acid or D-glucuonic acid 
and a D-glucosamine. R can be H or SO3
-
, R’ can be SO3
-
or COCH3. 
1.6.2 HS chain 
The structure of HS chains is a consequence of their biosynthesis. The chains are not 
homogenously sulfated, so they possess domains of varying sites that are not sulfated (NA 
domains) containing one glucosamine in two N-sulfated (transition or NAS domain) and 
sulfated domains in which every glucosamine is N-sulfated (S-domain). The latter look more 
like heparin, but are generally less O-sulfated [27]. S and NAS domains of HS chains are the 
sites where proteins bind [30]. 
HS polysaccharides are synthesized as covalent complexes with core proteins forming 
heparan sulfate proteoglycans (HSPGs). The sugar attachment consensus sequence consists 
of a Ser-Gly sequence flanked by at least two acidic amino acid residues. Three major 
families of HSPGs have been characterized. They include the transmembrane syndecans 
(four members in mammals), the glypicans, proteins attached to the cell membrane by a 
glycosyl-phosphatidyl-inositol (GPI) anchor (six members) and ECM proteins such as 
L-iduronic acid  D-glucosamine 
 or  
D-glucuronic acid  
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perlecan, agrin and collagen XVIII. There are other core proteins, which carry HS chains 
facultatively, sometimes as a result of alternative splicing of their mRNA. The core protein 
addresses the HS chains to different locations; syndecan and glypicans to the plasma 
membrane, matrix core proteins to the extracellular matrix/basement membrane [31]. 
1.6.3 Heparin vs HS 
Each disaccharide unit of heparin chains contains an average of 2.7 sulfates, in contrast, HS 
contains less than 1 sulfate in each disaccharide. So, heparin has a higher charge density for 
binding to proteins than HS [32]. However, the domain structure of HS means that S-
domains in particular have a charge density that is considerably higher than the average for 
an HS chain, though still lower than that of heparin. Thus, heparin and HS share similar 
structures, so, heparin can mimic the binding activity of HS towards FGFs [33]. 
1.7 FGFR binding 
1.7.1 FGFR structures 
FGFR1-4 are transmembrane proteins, their structure comprises three parts: an extracellular 
portion, which  binds ligands and HS, a transmembrane helix and a tyrosine kinase domain 
[34]. FGFR1-4 have a degree of identity of between 55-72 % of the total amino acids 
sequences and ~ 32 % identity of the extracellular domain. For FGFR1-4, the extracellular 
region contains two or three immunoglobulin Ig-like domains (D1, D2, and D3) (Figure 1.4) 
[34, 35]. There is an unusual sequence of acidic amino acids (the acid box) between D1 and 
D2 [36]. There are also up to six possible N-glycosylation sites on D2 and D3, which affect 
ligand and heparin binding in vitro [37] and receptor activity in vivo [38]. Heparin and HS 
bind to D2 while the FGF ligand interacts with residues in D2 and D3 [39]. The intracellular 
part of the FGFR has a large juxtamembrane region to which the adaptor FRS2 binds, a split 
tyrosine kinase domain and a COOH terminal tail. There are two Tyr residues in the 
activation loop of the FGFR kinase and around six other Tyr residues which, when 
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phosphorylated, serve as docking sites for signaling molecules. The alternative splicing 
results in many isoforms of FGFR. For example, alternative splicing of exon 6 of FGFR 
hnRNAs produces the corresponding protein structures in D3 determining the ‘a’, ‘b’ and ‘c’ 
isoforms, with the ‘a’ isoform lacking an intracellular domain (Figure 1.4). The two 
FGFR5s (FGFR5β and FGFR5γ) were found later and they have a different structure 
compared with the other four FGFRs. FGFR5 does not have an acid box between D1 and D2 
and it lacks a tyrosine kinase domain (Figure 1.4) [40]. . 
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Figure 1.4 Schematic of the domains of FGFR [40]. 
FGFRs have 5 family numbers and each member has different isoforms. The major 
differences between these FGFR isoforms are shown. The main difference between isoforms 
β and γ, is that γ is missing the mRNA encoding the D1 domain and maybe also the acid box, 
and the acid box can be found in FGFR 1-4 [41-43]. The alternative splicing of exon 6 of 
FGFRs, for which the corresponding protein structures in D3 are coloured in grey, determine 
the “b” and “c” isoforms, and isoform “a” does not have an intracellular domain. FGFR5 
does not have tyrosine kinase. Minor isoforms, though with some functional significance are 
formed as a result of exon slippage at splicing sites. 
  
Intracellular 
domain 
Extracellular 
domain 
D1 
Acid Box 
D2 
 
D3 
Cell surface 
Tyrosine 
kinase 
 β γ b/c a FGFR5 
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Table 1.2 Isoelectric point (pI) and FGFR binding specificities of FGFs 
 
The theoretical pI was calculated using the online software protparam tool 
(http://web.expasy.org/protparam/) [44] and the FGFR binding specificities in sub-families 
are from Ornitz, et al. and Zhang, et al. [45, 46]. 
a. 
FGF-2 can bind to the FGFR5β and 
FGFR5γ, the binding affinity is less than FGFR2c, but was not compared to other FGFRs 
[47].  
 
1.7.2 Binding of FGFs to their receptors 
FGFs mediate their biological effects by binding to, dimerizing, and activating their FGFR, 
through transphosphorylation of their kinase domains. This initiates intracellular biochemical 
signal transduction by FGFs at the cell surface [48]. FGFs have distinct binding specificities 
for FGFRs (Table 1.4) [45, 46]. However, the selective binding of FGF ligands to their 
FGF subfamily FGF PI FGFR binding specificity 
FGF-1 sub-family FGF-1 6.52 All FGFRs 
FGF-2 9.58 FGFR 1c, 3c>2c, 1b, 4∆, 5βa, 5γa 
FGF-4 sub-family FGF-4 9.73 FGFR1c, 2c>3c, 4∆ 
FGF-5 10.54  
FGF-6 10.00  
FGF-7 sub-family FGF-3 10.88 FGFR2b>1b 
FGF-7 9.29  
FGF-10 9.61  
FGF-22 11.81  
FGF-8 sub-family FGF-8 10.44 FGFR3c>4∆>2c>1c>>3b 
FGF-17 10.43  
FGF-18 9.86  
FGF-9 sub-family FGF-9 7.06 FGFR3c>2c>1c, 3b>>4∆ 
FGF-16 9.22  
FGF-20 8.89  
FGF-19 sub-family FGF-19 6.55 FGFR1c, 2c 3c, 4∆ (weak activity) 
FGF-21 5.01  
FGF-23 9.17  
FGF-11 sub-family FGF-11 9.92 No known activity 
FGF-12 9.98  
FGF-13 9.92  
FGF-14 10.11  
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receptors is far from absolute. Only FGF-7 shows a high degree of fidelity, binding only to 
FGFR2c, whereas all other extracellular FGFs are capable of binding more than one FGFR 
isoform. At the other extreme is FGF-1, which is often called the "universal ligand", because 
it can bind all FGFRs to some extent. Nonetheless, specificity within each sub-family is 
conserved, except in the FGF-1 sub-family, due to the promiscuity of FGF-1 (Table 1.4) [45, 
46]. FGF-2 binds to FGFR5, but FGF-7 cannot [47], which again highlights the specificity of 
FGF-7. The binding specificity of other FGFs for FGFR5 is not known. 
1.7.3 FGFR binding site 
The binding sites of FGF ligands in FGFR are focused on parts of Ig loops D2 and D3, and 
also the linker between these two loops.  The first studies into the sites of interactions of 
FGFs and FGFR involved synthetic peptides [49], site-directed mutagenesis and isothermal 
titration calorimetric [50]. Subsequently, the structures of co-crystals of FGF ligand and the 
extracellular domain of FGFRs were solved.  In the crystal structure of FGF2-FGFR1 (PDB: 
1CVS) [51], a large number of amino acids residues in FGF-2 were reported to be involved 
in FGFR binding by hydrogen bonds, van der Waals and hydrophobic interaction. These 
interactions included 4 areas in FGF-2: F26, K30, Y33 and K35, located at the N-terminus, 
β1 stand and loop β1-2. The sequence 65-QAEER-69, which includes part of β4 and of loop 
β4-5 was also proposed to be part of the FGFR binding. Further along the sequence, V97, 
111-NYN-113, E105, L107, 108-DSN-110, located between loops β7-8 and strand β9 were 
observed to make contact with the receptor. Another five amino acids, 141-PG-142, L147, 
L149, M151 in loop β11-12 and also strand 12 interacted with the FGFR. Subsequently, 
another crystal structure, comprising a FGF-2-FGFR1-DP6 complex (PDB: 1FQ9) supported 
these binding sites [52].  
In the asymmetric FGF-1-FGFR2-heparin DP10 crystal structure (PDB: 1E0O) [53], there 
were also four areas with binding residues reported, which are quite similar to the sites of 
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interaction of FGF-2. The first one is located at β1 and loop β1-β2 (Y30, Y35 and Y37). 
Another three residues are located at loop β3-4 (R50 and R52) and loop 4-5 (V66). The third 
one includes E102, and two sequences 104-LEE-106 and 108-HYN-109, which are located 
between β8 to loop β8-9. The last one is located at β12, consisting of only two residues 
(L148 and L150). Later, in another crystal structure (FGFR3c-FGF1, PDB: 1RY7), another 
three residues, which are located at N-terminals were also reported (G21, Y23 and K24). 
In the FGF-10-FGFR2b crystal structure (PDB: 1NUN) [54], the amino acids reported to 
have interactions directly with FGFR again mapped to four areas on the molecular surface, 
which are at similar positions as those in FGF-1 and in FGF-2. The first one is between the 
N-terminus and β1 (71-HLLQGDVR-78, R80, F83 and F85). The second one is quite large 
from loop β3-4 to strand 6, which includes K102, E104, 113-ITSVEIG-119, V121 and Y131. 
Another area includes F146, 154-ERI-156 and 159-NGY-161, located between loop β7-8 to 
strand 9 [54]. The last one includes just two residues, which are L202 and M204 in strand 12. 
The crystal structure of FGF-8b-FGFR2c (PDB: 2FDB) also showed that the FGFR binding 
site is contributed to by four areas, which are similar to those in FGF-1 and FGF-2 [24]. The 
first one contains 11 residues: F50, H53, V54, Q57, D62, L64, R66, L68, R70, Y75 and R77, 
which map to part of the N-terminus and the whole of strand 1. The second one is between 
stands 4 to 5 and includes V106, T108, F111 and S113. The third one is located between β8 
to β9 and comprises E159, V161, L162 and 165-NYT-167. The last one is located at β12 and 
consists of 193-MKR-195.  
1.7.4 Activation of FGFR: binding models 
In pioneering studies, FGFs were shown to require heparin to stimulate cell division [55, 56]. 
Since then, many growth factors, including other FGFs have also been shown to be 
dependent on heparin/HS. It should be noted that there is evidence to show that FGFs can 
activate their receptors in the absence of the polysaccharide. However, the outcome of 
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signaling in the absence of the sugar is different to that in the presence of sugar, and only in 
the latter case can FGFs exert their full range of effects, including the stimulation of cell 
division [57-61]. To explain this dependence on the sugar in the formation of a signaling 
complex, three different binding models have been proposed. The first model was 
established by Pantoliano, et al. in 1994 using isothermal titration calorimetry (ITC), site 
directed mutagenesis and molecular modeling.  This is usually called the growth hormone 
model [62]. Later, crystallographic analysis of binary FGF-FGFR and ternary FGF-FGFR-
heparin complexes has provided another two models for FGFR dimerization, the symmetric 
(dimer of dimers) model and the asymmetric model [52, 63, 64]. 
1.7.4.1 Growth hormone model 
In the growth hormone model the FGF-2 ligand is bivalent, with one high and one low 
affinity binding site binding two receptors, with the heparin glueing the complex together; 
the low affinity binding site of the FGF-2 that binds to the second FGFR is effective because 
this second stage of complex formation occurs in the 2-dimensional confines of the 
membrane [62]. So, the FGF-2 and HS are like bridges, linking the two FGFRs [62]. Also, 
site mutagenesis showed that while the disruption of the secondary FGFR binding site did 
not decrease the binding of the high affinity site to the FGFR and HS, it reduced the 
mitogenic potency [50]. Later, a site-directed mutagenesis and loop replacement study of the 
FGF-7 binding complex with FGFR2c also supported this model [65]. 
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Figure 1.5 Three models of the FGFR signaling complex. 
The “F” is FGF, which is coloured in green. Only receptor Ig D2 and D3 are shown in these 
models, which are coloured in orange. Heparin chains are coloured in black, NRE: non 
reducing end, RE: reducing end. A. Growth hormone model. B. Symmetric model. C. 
Asymmetric model. 
1.7.4.2 Symmetric dimer model 
In the symmetric two-end model, heparin promotes dimerization of two FGF-FGFR 
complexes by stabilizing bivalent interactions of the ligand and receptor through primary and 
secondary sites and by stabilizing direct receptor-receptor contacts [52]. The two FGF-
FGFR-HS/heparin complexes arise from back-to-back interactions, with reducing ends of 
sugar chains facing each other (Figure 1.5). The symmetric dimer model is based on the 
crystal structure of the FGF-2 bound to D2-D3 of FGFR1 (PDB: 1FQ9) [51, 52, 63]. In this 
model, two 1:1(FGF: FGFR) complexes form a symmetric dimer. FGF ligand to receptor 
interactions include both the interaction directly between the two molecules and the 
interaction of the FGF bound to the FGFR of the adjoining complex, which is proposed to 
help stabilize the dimer. However, no FGF to FGF interactions were observed. Later another 
dimeric assembly of two 1:1 (FGF1:FGFR2) complexes was determined, which supports this 
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model [66]. Another two FGF-FGFR crystal complexes were established afterwards, FGF-
10-FGFR2b and FGF-8b-FGFR2c, again supporting this model.  
1.7.4.3 Asymmetric model 
A fundamentally different model (asymmetric model) for FGF signaling complex was 
proposed based on the crystal structure of a FGF-1-FGFR2c-heparin complex (PDB: 1E0O) 
[53]. In the asymmetric model, there are no protein-protein contacts between the two FGF-
FGFR complexes and these are linked only by the sugar [53] (Figure 1.5). Heparin binds to 
both FGFs, but binds only one FGFR. Also, each FGF binds to only one FGFR and there are 
no contacts between the two FGFRs.  
1.7.4.4 Symmetric vs. Asymmetric 
The major differences between the asymmetric and the symmetric model include an 
invariant proline in the D2-D3 linker region of the FGFR form in cis conformation, whereas 
in the symmetric 2:2:2 model, this proline is in a trans conformation [52, 53, 67]. 
Following the publication of these proposed models, there was considerable argument as to 
which was correct. Harmer et al. used a combination of size-exclusion chromatography, 
analytical ultracentrifugation and mass spectrometry to present data suggesting that both 
types of dimer can coexist [68]. However, these models may not explain other biochemical 
and biophysical data, such as the ability of at least FGF-2 to induce the transient activation of 
the MAP kinase pathway in the absence of sugar [57, 59-61]. The asymmetric model, which 
relies on the linkage by the sugar chain, may have difficulty accommodating a 
tetrasaccharide, which is the shortest oligosaccharide capable of allowing FGF-2 to stimulate 
cell proliferation [57]. Moreover, site-directed mutagenesis that reduces the secondary FGF-
FGFR interactions results in diminished FGFR activation, presumably due to decreased 
dimerization, without affecting ligand-receptor binding [69]. This can be explained by the 
symmetric two-end model, but not the asymmetric model. However, since many of the 
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receptor-receptor contacts in the symmetric two-end model are due to the peptide backbone, 
such experiments are not necessarily as conclusive as they appear at first sight. 
1.8 Non-signaling Functions of HS binding 
Since heparin was found to promote the activity of FGF-1 on endothelial cells [70], the 
binding of FGFs to HS/heparin has been progressively investigated. As well as promoting 
the growth stimulatory activity of FGFs by forming ternary complexes with the FGFR, the 
interaction of these growth factors with the polysaccharide influences other important 
aspects of their activity: conformation, stability and transport.  
Conformational change and stabilization of FGFs-The interaction of FGF-2 with heparin and 
HS has long been associated with conformational change in the protein. Thus, it was 
established that heparin protected FGFs against pH-dependent degradation and proteolysis, 
and increased the thermal stability of the proteins [71, 72]. Some conformational change in 
FGFs has also been reported in experiments that measured the secondary structure of FGFs in 
solution by infra-red spectroscopy [73]. However, the structures derived from X-ray 
crystallography do not support these effects of heparin, because in co-crystals of FGFs with 
oligosaccharides derived from heparin, the alpha carbon backbone is superimposable on that 
observed in crystals made from the protein alone [74-77]. Nonetheless, the earlier 
biochemical and biophysical data cannot be disregarded and the question of the extent of 
conformational change in FGFs induced by their binding the sugar needs to be re-addressed. 
Transport and storage-Not long after FGFs were found to bind to heparin and HS, the 
storage of FGFs in HS of the extracellular matrix was noted [78-80] and various mechanisms 
for the release of such stored FGF were discovered [31, 78, 81-84]. These include release of 
FGF-2 from the HS chains of PGs in the matrix by the action of heparanase, as observed in a 
skin wound healing model [85].  The released FGF-2 was proposed to be a key early 
component in the signaling required to heal skin wounds. In development, differences in the 
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storage capacity of HS in resting versus developing tissue were observed in the developing 
rat mammary gland. The high storage capacity of HS along resting ducts was attributed to 
their quiescent state, whereas the lack of any storage in terminal end buds, a site of active 
ductal elongation, was suggested to relate to the active transport of FGFs between the stroma 
and the epithelium [80].   
1.9 The interaction of FGFs with heparin 
Owing to the importance of the interactions of FGFs with HS and its experimental proxy 
heparin these have been subject to a large amount of experimental analysis.  Most data relate 
to the archetypal FGFs, FGF-1 and FGF-2.  
Heparin was found to increase FGF-1 mitogenic activity first in the 1980s [70, 86]. Later, 
Lys-118 in FGF-1 was found to strongly bind heparin and it was reactive because it was in a 
unique micro environment. This work also showed that clusters of basic residues are 
important for heparin binding [87]. One of the first systematic analyses was of a series of 
nested peptides derived from the sequence of FGF-2 [49]. This study identified sequences of 
FGF-2, 24-68 and 106-115 as having the ability to bind heparin. Subsequently, the 
interaction of FGF-2 with heparin was probed by a combination of site directed mutagenesis, 
heparin chromatography and isothermal titration calorimetry [88]. This study showed that 
wild-type FGF-2 was eluted at 1.38 M NaCl [88], whereas FGF-2 with mutations of selected 
arginines and lysines eluted with 0.46-0.26 M NaCl. The binding of FGF-2 to heparin was 
characterized by a single binding constant (KD=0.47 µM) in 0.1 M NaCl, and 30 % of the 
free energy of binding derived from ionic bonding [88]. Subsequent quantification of the 
biophysical binding parameters of FGF-2 binding to heparin-derived oligosaccharides of 
different lengths in an optical biosensor showed that there is no interaction with DP2 [57]. 
FGF-2 did bind with DP4 (KD=62±28 nM), the highest affinity being for DP8 (KD=11±2 
nM), which then decreased as the sugar length increased. The kinetics of interaction had a 
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fast association rate constant (~10
6 
M
-1
s
-1
), characteristic of ionic interactions, where 
coulombic steering increases the collision cross section of the molecules.  The very different 
affinities found in these two studies highlights some of the difficulties in the field. In 
calorimetry, binding sites must be saturated, whereas in kinetic measurements in optical 
biosensors only the highest affinity site is probed.  Since heparin and HS are polydisperse, 
presenting different qualities of binding sites to FGF-2, the two techniques report quite 
different affinities. 
1.10 Complexity and Specificity 
The regulation of FGF activity by HS represented the second major biological function for 
these glycosaminoglycans, the first being the regulation of coagulation. There are now at 
least 435 proteins that bind heparin/HS in the plasma membrane and extracellular matrix of 
mammalian cells [89, 90]. Their interactions with HS controls many facets of their activities.  
The FGFs remain a key model for these protein-sugar interactions; ideas derived from 
experiments on the FGF ligand-receptor system become the starting hypotheses for these 
other protein-HS interactions. Therefore, questions relating to the specificity of the 
interactions of FGFs with HS/heparin are important beyond the FGF field. In the FGF 
signaling system heparin/HS was shown to be essential for FGF signaling and there is 
evidence for the FGF ligand-receptor system possessing a high degree of specificity. For 
example, HS from different tissues is clearly able to support the assembly of specific FGF 
ligand-receptor complexes [91]. According to other evidence, specific minimal chain length 
and selective of sulfation of heparin-derived sugars are needed for assembly of FGF-FGFR 
complexes. For example, DP8 has been suggested to be the minimal length required to 
enable FGF-1 and FGF-2 interactions with FGFR1 or FGFR2 and to induce ligand-receptor 
dimerization; 6-O-sulfate, though not required for ligand binding is thought to be essential 
for complex assembly and receptor dimerization [92, 93]. By removing 2-O- and 6-O- 
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sulfates, heparin can be reduced to activating only FGF-1 with FGFR-2, but not FGF-1 with 
FGFR-1 or FGF-7 with FGFR2b [93]. In other studies heparin oligosaccharides of different 
sizes or of modified structure were tested with FGF-1, FGF-2 and FGF-4. The results 
showed that at least a decasaccharide was required for high affinity interaction with FGF-1, 
FGF-2 and FGF-4 [94, 95] and that FGF-2 required both  2-O-sulfate  groups  and  the  
negative  charge  of the  carboxy  group  in  iduronate  residues  to bind to oligosaccharides, 
whereas  6-O-sulfate was required for FGF-1 and FGF-4 binding. However, DP4, though not 
as effective as DP8, has been shown in other experiments to be sufficient for assembly of a 
signaling complex and able to bind FGF-2 with good affinity [57]. 
At the level of binary complexes, in vitro,  HS isolated from different cell types has different 
binding kinetics for FGF-1 and FGF-2, spanning from 22±6 to 290±70 nM for FGF-2 and 
400±130 to 8600±2500 nM for FGF-1 [96], suggesting that FGF-1 and FGF-2 bind 
differently to different HS structures. However, there are other views, which state that 
different FGFs bind to HS oligosaccharides with similar relative affinities and low selectivity, 
such that the strength of these interactions relies more  on the overall level of sulfation than 
other characteristics [97]. Also, different members of the FGF family have been suggested to 
share binding sites on HS chains [98, 99]. The constrasting biophysical data from ITC and 
opitical biosensor, where a 10-fold difference in KD was measured (Section 1.9) highlights a 
key issue. These experiments are quantitative and their differences readily explained by the 
necessary differences in experimental design. A clear conclusion from this work and later 
studies on HS [96] is that FGFs do indeed recognize a range of sites in the polysaccharide. 
Many other studies have used indirect and qualitative measurements of affinity. One of the 
most common is the concentration of NaCl required for elution from heparin. Such approach, 
as has been reviewed [27] may confound it over interpreted. Thus, although the broad picture 
of the activity of FGFs being controlled by HS is accepted, there is considerable 
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inconsistency as to how specific the interaction of FGFs with the sugar are, what is the 
affinity and how ligand, receptor and sugar come together to form a signaling complex. 
1.11 Rationale & Aims 
Most of the FGF family members mediate their bioactivity by binding to HS. There is 
evidence for FGFs possessing different specificities with respect to their interactions with 
HS and the assembly of receptor-ligand complexes. However, studies have been heavily 
biased to the first members of the family to be discovered, FGF-1 and FGF-2, which belong 
to the same subfamily and experiments have often employed techniques that report the ionic 
component of the interaction rather than the actual affinity. Since the FGFs are all related, 
and arose through genome duplication and natural selection, they provide an excellent 
system for the analysis of whether protein structure specifies heparin binding specificity. 
Importantly, the functional consequences of a particular mode of heparin binding can be 
tested. The aim of this thesis is to produce a panel of FGFs from different subfamilies and 
determine the structure in the proteins responsible for heparin binding and their preferred 
sugar structures. This information can then be used to interpret the structural basis for 
different binding specificities and assemblies. Moreover, it should allow a critical test of 
whether FGF-sugar interactions do indeed exhibit a degree of specificity, since this would be 
expected to be under positive selection pressure and so follow, at least to some extent, the 
functional diversification of the FGFs. That is, sugar binding specificity, like FGFR binding 
specificity (Table 1.2), would be expected to be retained within FGF families, but to differ 
between sub-families. 
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Chapter 2 General Materials and Methods 
2.1 Electrophoresis 
2.1.1 Materials 
2-log DNA marker (New England Biolab, Herts, UK) 
SDS-PAGE markers (Bio-Rad, Laboratories Ltd, Hemel Hempstead, UK) 
Coomassie brilliant blue (CBB) (R) (Bio-Rad) 
2.1.2 Agarose gels 
Agarose gels (1.2 %, w/v) were made as follows: 
Agarose (1.2 g) was diluted and melted in 100 mL TAE (tris-acetate-EDTA) buffer (40 mM 
Tris, 20 mM acetic acid, and 1 mM EDTA, pH 8), then 10 µL 10,000× SYBR (New England, 
Biolab) was added into the agarose. The liquid agarose was added to the gel making kit and 
allowed to cool. Electrophoresis was carried out at 100 V, 30 min for each gel. 
2.1.3 SDS PAGE and Western blot 
2.1.3.1 Buffers 
Sample buffer (5×): 50 % (v/v) glycerol, 10 % (w/v) SDS, 25 % (v/v, freshly made) 2-
mercaptoethanol  in 315 mM Tris-HCl, pH 6.8 and coloured with bromophenol blue. 
Running buffer: 50 mM Tris, 192 mM glycine and 0.1 % (w/v) SDS. 
2.1.3.2 SDS-PAGE 
SDS-PAGE (15 % (w/v) acrylamide resolving gels and 4 % (w/v) acrylamide stacking gels) 
was made according to a published method [100]. The following (Table 2.1) were mixed 
together; gels were poured in a Bio-Rad (Bio-Rad) mini protein gel system apparatus with 
0.75 mm spacers. Electrophoresis was carried out at 200 V, 1 h/30 mA for each gel. 
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Table 2.1 SDS-PAGE  
A, Resolving gel. 
 
B, Stacking gel.  
Acrylamide/ bis-acrylamide stock (30 %, w/v) 1.3 mL 
Tris-Cl (1.25 M), pH 6.8   1 mL 
Water 3.7 mL 
10 % Sodium dodecyl sulphate (SDS) w/v 100 µL 
TEMED 20 µL 
Ammonium persulphate 50 mg/mL (freshly made) 100 µL 
 
Ingredients for 15 % (w/v) gel. A, 10 mL for 2 resolving gels; B, 6.22 mL for 2 stacking gels 
(Section 2.1.3.2). 
 
Clear liquid samples were mix in the ratio 4:1 (v/v) with 5× sample buffer. Five µL cell 
samples were mixed into 50 µL of 1× sample buffer. The mixed samples were heated to 
100
o
C for 2 min and centrifuged at 10,000 ×g for 5 min to remove any insoluble material. 
Electrophoresis was carried out at 30 mA, 200 V, 1 h for each gel. 
2.1.3.3 Coomassie Stainning  
The gels were soaked in Coomassie Stain (0.25 % (w/v) CBB (R), 40 % (v/v) methanol, 10 % 
Acrylamide/ bis-acrylamide stock (30 %, w/v)  5 mL 
Tris-HCl (3 M), pH 8.85  2.5 mL 
Water 2.5 mL 
10 % Sodium dodecyl sulphate (SDS) w/v 100 µL 
TEMED (N,N,N’,N’,Tetramethylethylene diamine) 10 µL 
Ammonium persulphate 50 mg/mL (freshly made) 100 µL 
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(v/v) acidic acid) for up to 20 min, then destained in destain buffer (30 % (v/v) methanol, 10 % 
(v/v) acidic acid) until the background became clear. 
2.1.3.4 Silver staining  
The gel was incubated in fixer (40 % (v/v) ethanol, 10 % (v/v) acetic acid, 50 % (v/v) H2O) 
for 1 h. Then, the gel was washed in 10 % (v/v) ethanol 3 × 5 min and in H2O for 3 × 5 min 
to reduce background staining and increase sensitivity. The gel was incubated in 0.02 % (w/v) 
silver nitrate solution for 30 min with gentle shaking. After washing in H2O for 5 s, the gel 
was washed once with freshly made developer (3 % (w/v) Na2CO3, 0.05 % (v/v) 
formaldehyde) and then incubated in developer until the level of staining was sufficient. 
Staining was stopped with a 5 min incubation in 1 % (v/v) acetic acid. The gel was left to 
wash in H2O for 6×5 min. The gel was cleaned by reducer (12 mM Na2S2O3, 4.6 mM 
K3[Fe(CN)6], 4.7 mM Na2CO3), and then with another 6×5 min wash with water until dry. 
2.1.3.5 Gel drying 
The gels and two pieces of cellophane were wetted in gel drying buffer (2 % (v/v) glycerol, 
20 % (v/v) ethanol). Gels were placed between two pieces of cellophane and clipped on the 
gel drying kit until dry. 
2.2 Mutagenesis 
Polymerase Chain Reaction (PCR) (KOD Hot Start DNA polymerase, Novagen) was 
undertaken to alter DNA sequences in plasmids with designed primers.  
The mutagenesis PCR system conditions with a total volume of 50 μL, followed by the 
general PCR method as shown in (Table 2.2).   
One μL Dpn1 was then used to digest the PCR product, at 37oC 1 h. Competent DH5α E.coli 
cells were thawed on ice. Ten μL of ligation product was mixed with 70 μL bacterial cells 
and incubated on ice for 30 min. Plasmids were permeated into cells by heat shock (1 min at 
42
o
C). After incubation for 2 min on ice, cells were rescued with 1 mL LB broth and 
incubated at 37
o
C for 60 min. Bacteria were collected by centrifugation at 3,500 ×g for 5 min 
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and resuspended with 100 mL of LB. Ten µl was plated out onto LB-amp plates (LB 
supplemented with 100 mg/mL of ampicillin (Sigma-Aldrich Ltd. Dorset, UK)). Plates were 
incubated overnight at 37
o
C. 
A single colony from the plates was added to 10 mL LB culture (ampicillin), grown 
overnight (37
o
C, 250 rpm). Cells from the overnight culture were collected by centrifugation 
(5 min, 2,500 ×g).  
2.3 Cloning  
2.3.1 PCR 
cDNAs were amplified by PCR using 50 µL systems, PCR conditions are shown in Table 
2.2 
Table 2.2 PCR conditions. 
A, PCR reaction mixture  
Contains Volume 
25 mM MgCl2 :             3 μL 
dNTPs :                                                    5 μL 
Primers (forward and reverse):    2.0 μL each (30 μM) 
Hot start polymerases: 1 μL 
DNA template:   2 μL (30-300 ng/μL) 
Hot start polymerase buffer 5 μL 
H2O :                                                             30 μL 
 
B, PCR cycle setting 
 Stage 1 Stage 2 Stage 3  
Cycle number: 1 30 1 finish 
Temperatures (
o
C) 98 95 Tm 72 72 4 
Time (s) 120 15 15 40/120 600 forever 
 
A, PCR reaction mixture; B, PCR cycle setting  
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2.3.2 Digestion 
Double restriction enzyme digests were conducted at 37
o
C in a water bath for at least 2 h, 
and the conditions are shown in Table 2.3. 
Table 2.3 PCR products  restriction digests and plasmids. 
Contains Volume 
DNA 5 μL 
Buffer (according to manufacturer’s instruction) 2 μL 
Nco1  2 μL  
Kpn1 (Sal1 or EcoR1) 2 μL 
10× BSA (1 mg/mL) (according to manufacturer’s instruction) 2 μL 
water  11 μL 
 
2.3.3 Ligation 
FGF cDNAs were ligated with vector plasmid by T4 ligase (T4 DNA ligase M0202L, New 
England Biolabs, UK) 15 min at room temperature, the ligation condition is shown in Table 
2.4. 
Table 2.4 Digest FGF cDNAs and pETM-11 plasmid ligation conditions 
Vector pETM11 (digested with enzymes) 1.5 μL 
DNA (from the digest) 2.5 μL 
 ×2 buffer  5 μL 
T4 ligase  1 μL 
Total  10 μL 
  
2.4 Bacterial culture strains 
2.4.1 Bacterial culture 
Lysogeny Broth (LB) culture was made following the instructions of the manufacturer (Merk, 
East Yorkshire, UK). 
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Terrific Broth (TB) culture: 1 L contained: 2.4 % yeast extract (w/v), 1.2 % tryptone (w/v), 
0.4 % glycerol (v/v), 17 mM KH2PO4, 72 mM K2HPO4, 50 µM FeCl3, 10 µM MgCl2, 10 µM 
ZnCl2, 2 µM NiCl2, 1 µM CoCl2. 
2.4.2 Competent cells  
2.4.2.1 Competent cells list 
DH5α cells (stored in -80oC); CL41 cells (stored in -80oC); BL21 (DE3) plysS cells (kind 
gift from Dr. Roger Barraclough). T1, RG (blue) and Rosetta Competent cells (ORIGAMI 
TM
 
Technology). 
2.4.2.2 Preparation of stocks of CL41 (DE3), DH5α and BL21 (DE3) 
plysS competent cells  
A single colony was added to 5 mL LB and incubated overnight at 30
o
C, 250 rpm. Five mL 
overnight culture was transferred into 100 mL LB, and incubated at 30
o
C, then incubated at 
250 rpm for 1.5 h (until the OD600 reached 0.3-0.6). Cells were centrifuged 10 min, 3,500 ×g, 
at 4
o
C. The supernatant was removed and 20 mL 50 mM CaCl2 (chilled) was added and then 
the tube was left on ice for 30 min. Cells were then centrifuged as above after which 8.5 mL 
50 mM CaCl2 (4
o
C), and 1.5 mL 50 mM glycerol (15 %, v/v) were added to resuspend the 
cells, which were then stored at -80
o
C in aliquots. 
2.4.3 Transformation 
One hundred ng of plasmids were placed on ice together with 70 µL competent cells for 30 
min, 1 mL LB culture was added and the mixture incubated at 37
o
C for 1 h in a shaker 
culture (250 rpm). Then, the cells were collected by centrifugation and 1 in 5 of the cells 
were plated onto a LB Aar plate with antibiotic (dependent on the plasmids). 
2.4.4 Miniprep 
A single colony from the plates was added to 10 mL LB-Kanamycin (LB-Kan) culture, 
grown overnight at 37
o
C, 250 rpm. The overnight culture was then centrifuged 5 min, 2,500 
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×g, to collect the cells. Plasmids in the cells were purified using a Qiagen miniprep kit, 
according to the manufacturer’s instructions (Qiagen, UK). 
2.4.5 Sequencing 
Plasmid DNAs (30-100 ng/µL) were sent to Dundee Sequence (University of Dundee, UK) 
or GATC sequence service (GATC, UK) for sequencing. 
2.5 Protein expression 
A single colony was inoculated into 10 ml of LB with antibiotic (according to plasmids) 
overnight at 37
o
C in a shaking incubator (250 rpm).  
2.5.1 IPTG induction 
Three mL of the overnight culture were inoculated into 500 mL LB culture with antibiotic 
(according to plasmids). Several flasks of culture were set up, depending on the amount of 
protein required. Cultures were grown at 37
o
C (250 rpm) until an OD600 of 0.5~0.8 was 
reached. The expression of the protein was then induced with IPTG (Bioline UK, London, 
UK) at a final concentration of 1 mM under shaking at 250 rpm, for 3 h at 37
o
C or 16 h at 
16
o
C, depending on the FGF.  
2.5.2 Self induction 
Three ml of the overnight culture was inoculated into 500 mL TB culture with antibiotic 
(according to plasmids). Cells were grown at 37°C and cells were cooling down to 22°C and 
FGF production induced at 22°C for 16 h. 
2.5.3 Cell harvest 
Flasks were chilled on ice. The cultures were transferred to pre-chilled, sterile 500 mL 
centrifuge tubes and centrifuged for 20 min, at 7,000 ×g, 4
o
C.  
Cell pellets were resuspended with 25 mL of pre-chilled sterile phosphate-buffered saline 
(PBS: 137 mM NaCl，2.7 mM KCl，10 mM Na2HPO4, 2 mM KH2PO4, pH 7.2) and 
transferred to 50 mL tubes, and centrifuged for 15 min, at 3,500 ×g, 4
o
C. Pellets were 
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resuspended with 10 mL of Resuspension Buffer (50 mM Tris-HCl pH 6.8, 0.6 M NaCl, 1 
mM DTT) and stored at -80
o
C. 
2.6 Chromotography 
2.6.1 Chromatography columns 
Three mL of Affi-Heparin agarose (Bio-Rad); 1 mL Heparin column (Hi Trap heparin HP, 
GE Healthcare Ltd, Buckinghamshire, UK); 1 mL Q HP column (Hi Trap heparin HP, GE 
Healthcare); Probond Ni; 1 mL HiTrap column (GE Healthcare) 
2.6.2 Cell breakage 
Bacterial cells were thawed on ice and transferred to a pre-chilled 100 ml glass beaker. Cells 
were sonicated for 30 s (Dawe Ultrasonic Generator 7533A, pulsed sonication, max power, 
40 / 50 % duty cycle) and placed on ice for 1 min. The procedure was repeated 6 times. 
Samples were then centrifuged in pre-chilled sterile 50 mL centrifuge tubes at 17,000 ×g for 
30 min. 
2.6.3 Chromatography I 
A column (depending on the FGF) was first connected to a Pharmacia LKB-P1 peristaltic 
pump and equilibrated with washing buffer (according to which FGF) at a flow rate of 1 
mL/min. The supernatant from Section 2.6.2 was loaded on to the column, then washed with 
washing buffer for 2 h at the same flow rate. Protein was eluted with elution buffer 
(depending on which FGF). Elution was monitored at 280 nm with a Bio-Rad ECONO UV 
monitor (Bio-Rad) connected to a Kipp and Zonnen (Netherlands) recorder.  
2.6.4 TEV digestions  
Proteins eluted from chromatography I (Section 2.6.3) were buffer-exchanged into 50 mM 
Tris.HCl, pH 7.5, 0.6 M NaCl using a centrifugal filter column (10 K MWCO, Millipore Ltd, 
Watford, UK). TEV protease was added 1:20 (w/w) into the buffer-exchanged protein 
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solution and digest was at 4
o
C, overnight. The digested protein solution was loaded again 
into the nickel affinity column and the flow through was collected. 
2.6.5 Chromatography II 
The proteins eluted after chromatography I or after TEV digestion and Ni affinity 
chromatography was diluted or buffer-exchanged to a suitable concentration of electrolytes 
and then loaded onto a column (depending on the FGF) and eluted with a salt gradient using 
an AKTA TM HPLC system. Elutions were monitored at 214 and 280 nm and peaks 
collected in 1 mL fractions. Protein concentration was calculated by absorbance 
measurement at 280 nm (according to the calculated molar extinction coefficients)  
2.7 Mammalian cell culture 
2.7.1 Cell line 
Normal Rat, fast sticking fraction, Rama (rat mammary) 27 fibroblast cells were used [101] 
2.7.2 Tissue culture reagents 
1. RM (Routine medium): DMEM (Dulbecco’s modified Eagle medium) 1× (Gibco Life 
Technologies, Paisley, Scotland, UK), 10 % (v/v) FCS (foetal calf serum), 0.75 % sodium 
bicarbonate (w/v) (Invitrogen, Paisley, UK), 20 mM L-glucosamine (Gibco), 1,00 IU/mL, 
penicillin (Gibco), 100 µg/mL streptomycin (Gibco), 50 ng/mL insulin (Sigma-Aldrich), 50 
ng/mL hydrocortisome (Sigma-Approach). 
2. Trypsin/EDTA solution: 25 mL versene (0.5 mM EDTA in PBS, pH 7.2) containing 2.5 % 
trypsin (in PBS, w/v) (Gibco). 
3. BSA (bovine serum, albumin) (Sigma-Aldrich). 
4. SD medium (step down medium): DMEM, 250 µg/mL BSA. 
5. Freezing medium: DMEM supplemented with 7.5 % (v/v) DMSO (dimethyl sulphoxide), 
20 % (v/v) FCS. 
6. Isoton II counting fluid. 
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7. PBS (phosphate buffered saline): 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM 
KH2PO4, pH7.2. 
8. Tissue culture grade Petri dishes (Nunc, Roskilde, Denmark). 
2.7.3 Routine fibroblasts cells 
Rama 27 cells were incubated into 9 cm diameter dishes and grown in monolayer culture in 
RM at 37
o
C in a humidified atmosphere of 10 % carbon dioxide: 90 % air (both v/v). When 
the cell monolayer reached 60 % confluence, the cells were subcultured at a ratio of 1:8. The 
cells were washed with 5-10 mL PBS, then incubated in 1 mL trypsin/EDTA at 37
o
C 3-5 
min. When all cells detached, 7 mL RM was added into each plate and resuspended, taking 
care to ensure there were  no clumps of cells. One mL of resuspended cells was added into 
each new tissue culture dish (cells were split at a ratio of 1:8), and 9 mL medium was added 
per dish. Rama 27 cells were used within a narrow passage range between passages 30 and 
45 to ensure that the cells retained their growth characteristics. 
2.7.4 Determination of cell number 
A cell suspension (0.5 mL), obtained by passaging (Section 2.7.3), was added to 19.5 mL of 
Isoton II. The number of cells in a suspension was counted using a Coulter Electronics 
particle counter.  Two counts were collected on each suspension of cells and the mean was 
used to calculate the number of cells in the original suspension. 
2.7.5 Freezing cells 
Cells were collected by trypsinisation (Section 2.7.3), counted and collected by 
centrifugation in a universal tube at 700 ×g for 5 min.  After removing the supernatant, the 
cell pellet was resuspended in an appropriate volume of freezing medium to achieve a final 
cell density of 1-1.5 x 10
6
 cells/mL and l mL aliquots were transferred into 1.5 mL cryotubes. 
The aliquots were placed on dry ice for at least 1 h and then stored at -140
o
C.   
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2.7.6 Thawing 
The cells were thawed at 37
o
C, then the cells were removed from the cryotube and put in a 
25 mL universal tube. DMEM 20 % FCS was add slowly inside the tube to a total volume of 
20 mL. Then the cells were spun down at 700 ×g for 5 min. After removing the supernatant, 
pellets were resuspended with 10 mL RM and placed into two 3 cm diameter culture dishes 
in appropriate culture medium pre-warmed and incubated at 37
o
C. 
2.7.7 Cell fixing 
The cells on the dish surface were first washed with PBS for several times and then 
incubated in 4 % paraformaldehyde (PFA) (w/v, dissolved in PBS at 60
o
C) for 20 min. The 
fixed cells were washed again with PBS, and stored in PBS with 0.02 % (w/v) azide at 4
o
C. 
2. 8 DNA synthesis assay 
2.8.1 Reagents 
1. 40 µ Ci/mL [methyl-3H]-thymidine. (ICN, Basingstoke, UK)  
2. 5 % (w/v) TCA (trichloroacetic acid)  
3. 95 % (v/v) ethanol. 
4. 0.2 M NaOH.   
5. Foetal Calf Serum (FCS)  
6. BSA 
7. 10 mg/mL heparin dissolved in PBS  
2.8.2 Assay 
Cells were plated out from near confluent 9 cm dishes into 24-well tissue culture plates 
(Gibco) at 10,000-20,000 cells per well and incubated at 37
o
C for 24 h. After washing wells 
twice with 500 µL PBS, 500 µL SDM was added to each well and incubated at 37
o
C. 
Different concentrations of FGFs were added at least 24 h after step down to make a 
concentration gradient and then incubated for 18 h. At maximal DNA synthesis (max S 
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phase, 18 h for Rama 27 cells), 20 µL 40 µ Ci/mL [
3
H]-thymidine was added and incubated 
for 1 h. After washing cells with 2 x 500 µL PBS, 500 µL ice cold 5% (w/v) TCA (4
o
C) was 
added into each well and left for at least 30 min at 4
o
C. The wells were then washed with 1 x 
500 µL ice cold 5 % (w/v) TCA and TCA was removed by two washes with 95 % (v/v) 
ethanol.  Wells were left to dry and 500 µL 0.2 M NaOH was added to each well and left 
either overnight on the bench or at 37
o
C for 1h. Then, 300 µL solubilised TCA precipitate 
was transferred to each scintillation vial followed by 1 ml scintillation cocktail. Radioactivity 
was determined by counting for 10 min in a Packard tri Carb 1900TR scintillation counter. 
2.9 Differential scanning fluorimetry (DSF)  
The method corresponds to that previously described [102]. In brief, FGF solutions (10 % 
v/v), sugars (10 % v/v), 50× diluted 5000× sypro orange (10 % v/v) and PBS were mixed 
together. Ten µL of the mixture were added into Fast Optical 96 well plates (Applied 
Biosystems, Warrington, Cheshire, U.K.), each experimental condition had 3 replicates, and 
the plates were sealed with Optical Adhesive Film (Applied Biosystems). The samples were 
analyzed by real time RT- PCR machine (7500 Fast) with a temperature gradient from 32
o
C 
to 81
o
C: containing 99 time readings, with 0.5
o
C increase each reading. Data were collected 
by the installed software (7500 fast systems, Applied Biosystems) in the RT-PCR machine 
using the calibration setting for TAMRA dye detection (λex 560 nm; λem 582 nm). The 
original data were organized by Excel (Office 2007), and the first derivatives of the melting 
curves were calculated by Origin 7. 
2.10 Protect and Label  
This method was based on the previous publications [103]. Twenty µL slurry of AF-heparin 
beads (Tosoh Biosciences GmbH, Stuttgart, Germany) were packed into a micro column 
(made from a 50 µL tip, with a plastic air filter placed at its end to retain the heparin beads) 
with a 5 mL syringe.  The column was equilibrated with 4× 50 µL Buffer P1 (17.9 mM 
Na2HPO4, 2.1 mM NaH2PO4, 150 mM NaCl, pH 7.8) and loaded with 20 µg proteins by the 
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syringe. The loading was repeated 2 times. Then, the column was washed with 4× 50 µL 
Buffer P1.  
To block the amino groups, twenty µL Buffer P1 containing 50 mM sulfo-NHS-acetate 
(Pierce, Thermo Fisher Scientific p/a Perbio Science UK, Ltd., Northumberland) was first 
loaded into the column for equilibration, and then another 20 µL Buffer P1 containing 50 
mM sulfo-NHS-acetate loaded into the column and the reaction was left for 5 min at room 
temperature. Excess sulfo-NHS-acetate was removed by washing the column with 4× 50 µL 
Buffer P1. Then, bound proteins were eluted in Buffer P2 (44.75 mM Na2HPO4, 5.25 mM 
NaH2PO4, pH 7.8) with 2 M NaCl.  
Eluted proteins were diluted with 200 µL Buffer P2, and concentrated using a 5 kDa MWCO 
centrifugal filter (Sartorius Ltd, Epsom, UK) to a volume of 37 µL. After that, 2.8 µL 145 
mM NHS-biotin (Pierce) in DMSO (final concentration 10 mM) was added to the 
concentrated proteins and incubated at room temperature for 30 min to label the amino group 
previously protected by heparin binding. Four µL 1 M Tris, pH 7.5 was added to the solution 
to stop the reaction. The sample was desalted on a 0.5 ml desalting column (Zeba TM Desalt 
Spin column, Thermo, UK) following the manufacturer’s instruction and the desalted sample 
was then dried by centrifugal evaporation. The dried proteins were dissolved in 25 µL 8 M 
urea, 400 mM NH4HCO3 pH 7.8, 2.5 µL 45 mM DTT and incubated 15 min at 56
o
C. Then, 
2.5 µL freshly made 0.1 M iodoacetamide were added to carbamidomethylate SH groups for 
15 min at room temperature. The solution was dissolved in 70 µL HPLC grade water, and 
digested overnight with 1.5 µg chymotrypsin (Sigma-Aldrich) at 37
o
C.  
Peptides were diluted with 400 µL HPLC grade water and applied to a mini column, which 
contained a 25 µL slurry of Step-TactinTM Sepharose beads (IBA GmbH), equilibrated with 
4× 50 µL 500 mM urea, 25 mM NH4HCO3. The column was washed 3× 50 µL 500 mM urea, 
25 mM NH4HCO3 and then 2×50 µL HPLC grade water. Finally, bound peptides were eluted 
with two times 20 µL 20 % (v/v) trifluoroacetic acid (TFA), 80 % (v/v) acetonitrile (ACN), 5 
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mM biotin. The elute was desalted using a C18 ZipTipTM (Millipore) according to 
manufacturer’s instructions, and then analyzed by Tandem mass spectrometry (performed by 
Dr Ori, EMBL, Heidelberg).  
Up to 1 µg of biotinylated peptides were injected into a LTQ-Orbitrap Velos instrument 
(Thermo) using a nanoAcquity UPLC system (Waters Corporation, Manchester, UK). 
Peptides were separated on a BEH300 C18 (75 µm × 250 mm, 1.7 µm) nanoAcquity UPLC 
column (Waters) using a 60 min linear gradient (5-35 % (v/v) ACN in 0.1 % (v/v) formic 
acid). Data acquisition was performed using a TOP-10 strategy where survey MS scans were 
acquired in the orbitrap (R = 30,000 at m/z 400) and up to 10 of the most abundant ions per 
full scan were fragmented by higher energy collision dissociation (HCD) and analyzed in the 
orbitrap (R = 7,500 at m/z 400).  
Data analysis was performed using the Batch Tag tool of the Protein Prospector package 
v.5.9.2 (http://prospector2.ucsf.edu/) applying the following parameters: digest, 
chymotrypsin (FWYMEDLN); maximum missed cleavages, 5; possible modifications, 
acetyl (Lys), biotin (Lys), carbamidomethyl (Cys), oxidation (Met); parental ion tolerance, 
10 ppm; fragment ion tolerance, 0.05 Da. The UniProt accession number of the protein 
analyzed was used as a research parameter (database, SwissProt 2011.01.11). Results were 
filtered using a peptide E-value < 0.001 and SLIP score threshold for site assignment was set 
to 6 (cite PMID: 21490164). 
2.11 Biosensor binding assays 
Steptavidin (Sigma-Aldrich) was immobilized on amino silane surfaces (Farfield Group, UK) 
using bissulfosuccinimidyl suberate (BS3, Pierce) as the cross linker according to the 
manufacture’s recommendation. Controls showed that FGFs in PBST (140 mM NaCl, 10 
mM phosphate, pH 7.2, 0.02 % (w/v) NaN3, 0.02 % (v/v) Tween 20) do not bind to this 
surface, or a streptavidin surface. DP8 oligosaccharides were biotinylated with NHS (LC)-
biotin (Pierce) and then immobilized on to the streptavidin surface as described previously 
[57, 104]. The surface of the biosensor was inspected during every phase of the binding 
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reaction by examination of the resonance scans. The scans showed that the bound material 
was distributed on the curvette surface uniformly. 
A single assay consisted of adding the 1-5 µL different concentration FGFs into a cuvette 
containing 49-45 µL PBST to a total volume of 50 µL. The association was followed until 
binding was at least 90 % of the calculated equilibrium value, usually between 60 s-240 s. 
The cuvette was washed using 3 times with 50 µL PBST and regenerated with 2 M NaCl. 
The dissociation was measured using a fixed concentration with all FGFs (5 µL, 100 µg/mL 
FGFs diluted into a cuvette containing 45 µL PBST. When binding was maximal the cuvette 
was washed quickly with 3x 50 µL PBST and dissociation was followed three times over 60 
s. 
Binding parameters of the association and dissociation were calculated using the non-linear 
curve fitting Fastfit. Each binding assay yields several parameters: the slope of the rate of the 
association, the on-rate constant (kon) and the extent of binding, all calculated from the 
association phase and the off-rate constant, (koff, equivalent to the dissociation rate constant, 
kd), calculated from the dissociation phase [57, 105]. The association rate constant (ka) was 
calculated from the values of kon determined at five to seven concentrations of FGFs. The 
equilibrium dissociation constant (KD) was calculated from the ratio of the dissociation and 
association rate constant (kd/ ka). 
2.12 SRCD 
FGFs were buffer exchanged into CD buffer (15.3 mM Na2HPO4, 2.2 mM NaH2PO4, pH 7.5). 
FGFs (0.5 mg/mL – 1 mg/mL) and heparin were mixed in different ratios (1:5-5:1) and then 
were loaded into a quartz cuvette, pathlength 0.2 mm, and the spectrum was acquired from 
178 nm to 260 nm on beamline 23 (Olis DSM 20, Diamond). The program SELCON3 and 
the database 3 were used to analyze the secondary structures (software from 
http://dichroweb.cryst.bbk.ac.uk/htmL/home.shtmL). Each set of data was based on the 
average of four scans. 
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Chapter 3 Tools and Resources 
3.1 Subcloning of FGF cDNAs 
3.1.1 Materials 
pETM-11 (a modified pET-24b vector, kind gift from Dr Paul Elliott, University of 
Liverpool), which provides the sequences of the 6×Histag and the TEV cleavage site.pET-
14b-FGF-1 (UniProt Accession: P05230; residues: 16-155), pET-14b-FGF-2, (UniProt 
Accession: P09038-2; residues: 1-155),  pET-14b-Histag-FGF-2 (from Dr Laurence 
Duchesne, which contains a sequence encoding a 6× Histag and a thrombin cleavage site: 
MGHHHHHHLVPRGS at the N-terminus [106]), pETM-11-FGF-9 (Uniprot Accession: 
P31371 residues: 1-208). 
Plasmids containing human FGF-19, cDNAs pCMV-SPORT6-FGF-19 (UniProt Accession: 
O95750, residues: 25-216); human FGF-18 cDNA, pOTB7-FGF-18 (zFGF5) (UniProt 
Accession: O76093; residues: 28-207); human FGF-21 cDNA, pCMV-SPORT6-FGF-21 
(Uniprot Accession: Q9NSA1; residues: 29-209); human FGF-23 cDNA, pCR-BluntII-
TOPO-FGF-23 (UniProt Accession: Q9GZV9; residues: 25-251) were also acquired. 
Plasmids pCR2.1 containing FGF-3 (Uniprot Accession: P11487, residues: 18-239), FGF-5 
(Unipro Accession: P12034, residues: 18-268), FGF-7 (Uniprot Accession: P21781; residues: 
32-194), FGF-16 (Unipro Accession: O43320, residues: 1-207), FGF-17 cDNA (Unipro 
Accession: O60258, residues: 23-216) were shipped from the company undertaking gene 
synthesis (Eurofins mwg, UK).  
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Table 3.1 Restriction enzymes used for different FGFs 
fgfs enzyme1 enzyme2 
fgf-3 Nco1 Sal1 
fgf-5 Nco1 Kpn1 
fgf-7 Nco1 Sal1 
fgf-16 Nco1 Kpn1 
fgf-17 Nco1 Kpn1 
fgf-18 Nco1 Kpn1 
fgf-19 Nco1 Sal1 
fgf-21 Nco1 Sal1 
fgf-23 Nco1 Kpn1 
 
Table 3.2 Desalted PCR primers and cDNA. 
FGF Primer sequence TM (
o
C) 
FGF-5  Forward:     5’-ATTATCCATGGCATGGGCGCATGG -3’  46 
 Reverse:     5’-ATAATGGTACCTACCCAAACCGGAATTTCA-3’  46 
FGF-16 Forward:     5’-TATAATCCATGGCGGAAGTTGGCGGT -3’  48 
 Reverse:     5’-TTATGGTACCTACCTATAGTGGAACAGATC -3’  48 
FGF-18 Forward:     5’-ATTATCCATGGAGGAGAACGTGGACTTC -3’  50 
 Reverse:    5’- TAAATGGTACCCTAGGCAGGGTGT G -3’  50 
FGF-21 Forward:     5’- TATTACCATGGCACACCCCATCCCTGA -3’  51 
 Reverse:      5’- TCGTAGTCGACTCAGGAAGCGTAG -3’  51 
FGF-19 Forward:     5’-TAATCCATGGCTCTCGCCTTCTCGGAC -3’  53 
 Reverse:    5’-TAAGTCGACTTACTTCTCAAAGCTGGGACTCC -3’  53 
FGF-23 Forward:     5’-ATTATCCATGGCATATCCCAATGCCTCC -3’  50 
 Reverse:    5’-TAG CTG GTA CCC TAG ATG AAC TTG GC -3’  50 
FGF-19 Forward:     5’-ATGCTGCCTATGGTCCCAG -3’  58 
(mutagenesis) Reverse:     5’-GGGACCATAGGCAGCATGGGCAGGAAATGAGA-3’  58 
 
FGF-5, FGF-16, FGF-18, FGF-19, FGF-21 and FGF-23 PCR primers sequences (Invitrogen). 
Stock solution was 100 μM, Working solution was 30 μM. 
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3.1.2 Methods 
3.1.2.1 FGF-19 Mutagenesis (CCA→CCT) 
For ligation, Nco1 (CCATGG) digestion was used, to allow the insertion of the FGF-19 
cDNA into the pETM11 plasmid. However, the FGF-19 cDNA had an internal Nco1 
restriction site, so mutagenesis was needed to change a codon (CCA →CCT) according to 
the general method (Section 2.2).  
3.1.2.2 PCR and digestion 
Full length human FGF-18, FGF-19, FGF-21, FGF-23 cDNAs were obtained from Imagenes 
(Imagenes, UK) and full length human FGF-5 and FGF-16 cDNA were obtained by gene 
synthesis. These were all amplified by PCR with forward primers which contained Nco1 
restriction sites at their 5’ terminus and reverse primers which contained a Kpn1/Sal1 (Table 
3.1) restriction site at their 3’terminus (primer sequence: Table 3.2) (Section 2.3.1). 
3.1.2.3 Ligation 
FGF-5, FGF-9, FGF-16, FGF-18, FGF-19, FGF-21 and FGF-23 PCR products were digested 
withdouble enzymes according to Table 3.1 and ligated to digested pETM-11 (Section 2.3.3). 
3.1.3 Results 
3.1.3.1 Strategy for subcloning FGF cDNAs into pETM-11 
Full length human FGF cDNAs were amplified with forward primers, which contained Nco1 
restriction sites at their 5’ terminus and reverse primers, which contained Sal1 or Kpn1 
restriction site at their 3’terminus (Section 3.1.2.2). The PCR products were digested with 
Nco1 and Kpn1/Sal1, as appropriate, whilst the pETM-11 vector was digested with Nco1 
and Kpn1 (Section 3.1.2.2). The cDNAs were then ligated into the expression vector 
(Section 3.1.2.3).  
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3.1.3.2 Mutagenesis 
Internal restriction sites will cause the cloning strategy to fail. For example, in FGF-19 there 
is an Nco1 site at bases 510-512. Therefore, mutagenesis, performed by PCR on the whole 
plasmid was used to change the corresponding codon CCA→CCT, which eliminated the 
internal restriction site, but did not change the corresponding amino sequence of the cDNA 
(Section 3.1.2.1). 
3.1.3.3 PCR of cDNAs 
Six FGF cDNAs (fgf-5, fgf-16, fgf-18, fgf-19, fgf-21 and fgf-23) were amplified by PCR 
(Section 3.1.2.2), and the products were analyzed by agarose gel electrophoresis. The bands 
above 500 bp corresponded to a size expected of the FGF cDNAs.   
3.1.3.4 Ligation 
FGF cDNAs were ligated into the pETM-11 vector (Section 3.1.2.3). The expected products 
of the ligation were analyzed by transformation of the products into DH5α cells (Section 
2.4.3) and sequencing in both directions of the insert. Analysis of the returned sequences 
showed that they were identical to those of the corresponding FGF and the predicted amino 
acid sequences were also correct (result not shown). Quantification of the plasmids by their 
absorbance at 260 nm showed there was sufficient for transformation (FGF-18: 126.0 ng/µL, 
FGF-19: 91 ng/ µL, FGF-21: 110.8 ng/ µL, FGF-23: 124.0 ng/ µL). 
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Figure 3.1 Maps of expression plasmids. 
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FGF-3, FGF-5, FGF-7, FGF-16, FGF-17, FGF-18, FGF-19, FGF-21 and FGF-23 cDNAs 
(purple) were ligated into the pETM-11 vectors (which contain a 6× his-tag and a TEV-site). 
3.2 FGF expression and purification 
3.2.1 Methods 
3.2.1.1 Bacteria transformation 
One hundred ng pET-14-FGF-1, pET-14-FGF-2, pET-14b-Histag-FGF-2, pETM-11-FGF-9, 
pETM-11-FGF-18, pETM-11-FGF-21 were transformed into CL41 (DE3) cells separately, 
while 100 ng pETM-11-FGF-7 was transformed into BL21 (DE3) plysS cells, following the 
transformation protocol (Section 2.4.3). 
3.2.1.2 Bacterial cultures 
3.2.1.2.1 FGF-1, FGF-2 and His-tagged FGF-2 
Two liters (4× 500 mL) LB-ampicillin culture of C 41 cells contain pET-14b-FGF-1, pET-
14-FGF-2 or pET-14b-Histag-FGF-2 was induced with IPTG at a final concentration of 1 
mM for 3 h at 37oC (Section 2.5.1).  
3.2.1.2.2   FGF-7 
Two liters (4× 500 mL) LB- LB-Kan and chloramphenicol (Sigma-Aldrich) culture of C 41 
cells containing pETM-11-FGF-7 was induced with IPTG at a final concentration of 1 mM 
for 3 h at 37oC (Section 2.5.1).  
3.2.1.2.3  FGF-9 
Two liters (4× 500 mL) LB-kanamycin culture of C 41 cells containing pETM11-FGF-9 was 
induced with a self induction system (Section 2.5.2).  
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3.2.1.2.4  FGF-18 and FGF-21 
Two liters (4× 500 mL) LB-kanamycin culture of C 41 cells contain pETM11-FGF-18 or 
pETM11-FGF-21 was induced with IPTG at a final concentration of 1 mM for 16 h at 16oC 
(Section 2.5.1).  
 
3.2.1.3 Cell breakage 
Cell breakage was achieved in the resuspension buffer (20 mM phosphate buffer, 0.6 M 
NaCl, 1 mM DTT, pH 6.5), except FGF-9 where Buffer A9 (0.3 M NaCl, 50 mM Tris, 1 mM 
DTT, pH 7.4) was used, supplemented with 0.2 mg/ml lysozyme  (lysozyme, chicken egg 
white, Calbiochem, Nottingham, UK), 10 μg/ml DNase I (deoxyribonuclease I, from bovine 
pancreas, Sigma-Aldrich), 1 tablet of protease inhibitor (complete EDTA-Free, Protease 
Inhibitor Cocktail Tablets, Roche, West Sussex, UK), 0.2 % (v/v) Tween-20 and 5 % (v/v) 
glycerol (Section 2.6.2). 
3.2.1.4 Chromatography I 
FGF-1, FGF-2 and Histag-FGF-2 were loaded separately onto a three mL Affi-heparin 
agarose (Bio-Rad) column, which was equilibrated with washing buffer F11 (20 mM 
phosphate buffer, 0.6 M NaCl, 1 mM DTT, pH 6.5), and the proteins eluted with elution 
buffer F12 (20 mM phosphate buffer, 2 M NaCl, 1 mM DTT, pH 6.5) (Section 2.6.3).  
The FGF-9 was loaded onto a 5 mL heparin agarose column, which was washed with Buffer 
A9 until the absorbance returned to baseline. FGF-9 was eluted in Buffer B9 (50 mM Tris, 2 
M NaCl, 1 mM DTT, pH 7.5) (Section 2.6.3).  
FGF-7, FGF-18 and FGF-21 were loaded separately onto a three mL Ni Resin (Probond Lot: 
1202530 Invitrogen) column, equilibrated with washing buffer F71 (50 mM imidazole, 0.5 
M NaCl, 50 mM Tris.HCl, pH 7.9), and the proteins were eluted with elution buffer F72 
(500 mM imidazole, 0.5 M NaCl, 50 mM Tris-Cl, pH 7.9) (Section 2.6.3).  
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3.2.1.5 TEV digestions 
FGF-7 and FGF-18 eluted from the Probond resin were buffer exchanged and digested with 
TEV protease, then loaded again to Ni Probond resin (Section 2.6.4). 
 
3.2.1.6 Chromatography II 
The FGF-1, FGF-2 and Histag-FGF-2 previously eluted from the affinity heparin agarose 
were separately diluted 3 fold with Buffer 13 (20 mM phosphate buffer, 1 mM DTT, pH 6.5) 
to a final NaCl concentration of 0.5 M, then applied to a 1 mL Hi-Trap heparin column using 
the same buffer and eluted with a NaCl gradient 0.5-2 M using an AKTA system (Section 
2.6.5).  
Eluted FGF-9 was diluted 4-fold with 50 mM Tris-Cl and applied to a 1 mL HiTrap Ni 
column, and eluted with an imidazole gradient (50 mM to 500 mM imidazole) in 0.5 M NaCl, 
1 mM DTT, 50 mM Tris-Cl, pH 7.5 (Section 2.6.5). Eluted protein was dialyzed against 10 
mM phosphate, 1 mM DTT, pH 7.5.  
The flow through of second Ni Probond of FGF-7 and FGF-18 were then applied separately 
to a 1 ml heparin column using the same buffer and eluted with a NaCl gradient 0.6-2 M 
(Section 2.6.5). 
The FGF-21 elute peak was dialyzed against Buffer F21 (10 mM Tris-Cl, 1 mM DTT, 50 
mM NaCl, pH 8.0) at 4oC and and then applied to a 1 mL Q column using the same buffer 
and eluted with a NaCl gradient 0.05-1 M using  an AKTA system (Section 2.6.5). 
Protein concentration was calculated by absorbance measurement at 280 nm (extinction 
coefficient: FGF-1: 17545 M
-1
 cm
-1
, FGF-2: 16180 M
-1
 cm
-1
, his-tagged FGF-2: 16180 M
-1
 
cm
-1
, FGF-7: 35785M
-1
 cm
-1
, FGF-9: 20525 M
-1
 cm
-1
, FGF-18: 20775 and FGF-21: 14565 
M
-1
 cm
-1
).  
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3.2.2 Results of expression and purification 
3.2.2.1 Introduction 
Except for FGF-1 and FGF-2, all the other expressed FGFs possess an N-terminal 
hexhistidine tag and a TEV cleavage site (26 amino acids, 
MKHHHHHHPMSDYDIPTTENLYFQGA), which derived from the vector pETM-11 
sequence and provides one method for purification. The high affinity of all FGFs, except for 
the endocrine FGFs (FGF-19, FGF-21 and FGF-23), for heparin, provides an affinity method 
for purification. The plasmid also encodes a TEV protease site between the 6×his tag and the 
FGF protein. So, following TEV cleavage, reverse Ni
2+
 chelation chromatography can be 
used to remove the 6×his tag, the TEV protease (this has a non-cleavable 6×his tag) and 
unwanted contaminants that bind the Ni
2+
 column. Generally, heparin affinity 
chromatography is the method of choice, but if it is only partly successful, or in the case of 
the endocrine FGFs, Ni
2+
 chelation chromatography provides a route to producing very pure 
protein. 
3.2.2.2 Expression and Purification of FGF-1 and FGF-2 
3.2.2.2.1 Purification of FGF-1 
FGF-1 was produced using an existing plasmid from a culture of 2 L (Section 3.2.1.2) and 
the protein eluting from the Affi-Heparin agarose with 2 M NaCl (Section 3.2.1.4) was 
diluted and loaded on to a HPLC heparin affinity column (Section 3.2.1.6). Four fractions 
were collected (A10-A13), corresponding to the protein peak (Figure 3.2). These, along with 
samples corresponding to the starting material and unbound protein were analyzed by SDS-
PAGE. The results show that a single band, of ~17 kDa was present in fractions A10 to A13 
(Fig. 3.3). Measurement of the protein concentration by absorbance indicated that there was 
0.17 mg protein in A10, 1.4 mg in A11, 1.8 mg in A12 and 0.17 mg in A13. These fractions 
were stored as 100 µl aliquots in elution buffer at -80oC.  
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3.2.2.2.2 Purification of FGF-2 
FGF-2 was produced using the plasmid from a culture of 2 L (Section 3.2.1.2) and the 
protein eluting from the Affi-Heparin agarose column (Section 3.2.1.4) was diluted and 
loaded on to a HiTrap heparin affinity column (Section 3.2.1.6). The protein peak (A13-B1) 
eluted just after that for FGF-1 (Figs 3.4) in agreement with the known requirement for 
higher concentrations of NaCl to elute FGF-2 from heparin (Section 3.2.1.6). These, along 
with samples corresponding to the starting material and unbound protein were analyzed by 
SDS-PAGE. The results show that a single band, of ~18 kDa was present in fractions A13 to 
B1 (Fig. 3.4). Measurement of the protein concentration by absorbance indicated that there 
was 1.2 mg protein in A13, 1.5 mg in A14, 1.1 mg in A15 and 0.1 mg in B1. These fractions 
were stored as 100 µL aliquots in elution buffer at -80oC.  
3.2.2.2.3  Purification of His-tagged FGF-2 
His-tagged FGF-2 was produced using a 2 L culture (Section 3.2.1.2) and the protein eluting 
from the Affi-Heparin agarose column (Section 3.2.1.4) was diluted and loaded on to a 
HPLC heparin affinity column (Section 3.2.1.6). The protein peak (A12-B13) eluted similar 
to FGF-2 from heparin. These, along with samples corresponding to the starting material and 
unbound protein were analyzed by SDS-PAGE. The result shows that a single band, of ~17 
kDa was present in fractions A13 to B14 (Fig. 3.5). Measurement of the protein 
concentration by absorbance indicated that there was 2.1 mg protein in A13, 3.1 mg in A14, 
3.2 mg in A15 and 1.1 mg in B1. These fractions were stored as 100 µl aliquots in elution 
buffer at -80oC.  
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Figure 3.2 Chromatography of FGF-1 on HiTrap heparin. 
Single-step purification of FGF-1 protein from heparin elution (Section 2.6.3) using 1 mL 
HiTrap heparin column (loading buffer B1: 50 mM phosphate, 0.6 M NaCl, 1 mM DTT, pH 
6.5; elution buffer E1: 50 mM phosphate, 2 M NaCl, 1 mM DTT, pH 6.5; flow rate: 1 
mL/min; sample load volume: 30 mL). Solid line represents the absorbance at 280 nm. 
Dashed line represents conductivity. The peak was collected and analyzed by SDS-PAGE.  
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Figure 3.3 Analysis of fractions containing FGF-1 by SDS-PAGE. 
Bacteria from a 2 L culture were broken by sonication and the clarified supernatant loaded 
on a 3 mL column of heparin agarose. The 2 M NaCl eluate from this column was diluted 4 
fold and applied to a 1 mL heparin HiTrap column on an AKTA HPLC system (Section 
3.2.1). Elution was monitored at 280 nm (Fig. 3.2) and peaks collected in 1 mL fractions and 
were analyzed by SDS-PAGE followed by coomassie staining. The molecular weight of 
FGF-1 is ~17 kDa. Pellets = insoluble material following cell breakage; Load = sample 
applied to 3 mL heparin column; FT = flow through fraction; elution = 2 M NaCl eluate; 
A10-A13 = fractions from HiTrap heparin column. 
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Figure 3.4 Analysis of fractions containing FGF-2 by SDS-PAGE. 
Bacteria from a 2 L culture were broken by sonication and loaded on a 3 mL column of 
heparin agarose. The 2 M NaCl eluate from this column was diluted 4 fold and applied to a 1 
mL heparin column on an AKTA HPLC systems (Section 3.2.1). Elution was monitored at 
280 nm and peaks collected in 1 mL fractions and were analyzed by SDS-PAGE followed by 
Coomassie Staining. The molecular weight of FGF-2 is ~17 kDa. Pellets = insoluble material 
following cell breakage; Load = sample applied to 3 mL heparin column; FT = flow through 
fraction; elution = 2 M NaCl eluate; A10-B1, fractions from HiTrap heparin column. 
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Figure 3.5 Analysis of fractions containing his-tagged FGF-2 by SDS-PAGE. 
Bacteria from a 2 L culture were broken by sonication and loaded on a 3 mL column of 
heparin agarose. The 2 M NaCl eluate from this column was diluted 4 fold and applied to a 1 
mL HiTrap heparin column on an AKTA HPLC systems (Section 3.2.1). Elution was 
monitored at 280 nm and peaks collected in 1 mL fractions and were analyzed by SDS-
PAGE followed by coomassie staining. The molecular weight of His-tagged FGF-2 is ~18 
kD. Non-induced bacteria cultured in the absence of IPTG; induced, bacteria induced with 
IPTG; Pellets = insoluble material following cell breakage; Load = sample applied to 3 mL 
heparin column; FT = flow through fraction; elution = 2 M NaCl eluate; A12-B15, fractions 
from HiTrap heparin column. 
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3.2.2.3 Expression and Purification of FGF-7 
3.2.2.3.1 Expression 
FGF-7 was indicated to be toxic to E. coli cells according to a previous study [107]. BL21 
(DE3) plsS cells were used to fully repress the FGF-7 gene by producing T7 lysozyme (a 
special T7 polymerase-inhibitor), to avoid the expression of the toxic FGF-7 while the cells 
were grown to the appropriate density for protein production. 
3.2.2.3.2 Purification 
FGF-7 was produced using the plasmid described in Section 3.1.3.4 from a culture of 2 L 
(Section 3.2.1.2). The proteins from lysis were loaded onto a Ni column and the elution was 
then digested by TEV protease (Section 2.6.4). The second flow through (after overnight 
digestion) from the Probond Ni
2+
 resin column (Section 3.2.1.4) was diluted and loaded on 
to a HPLC heparin affinity column (Section 3.2.1.6). Three fractions were collected (A14-
B15) corresponding to the protein peak. These eluted before FGF-2, suggesting that similar 
amount of NaCl is needed to break the FGF7-heparin interaction (Figure 3.6). These 
fractions, along with samples corresponding to the starting material and unbound protein 
were analyzed by SDS-PAGE. The most obvious band, of ~17 kDa, was present in fractions 
A14 to B15 (Figure 3.6 B). Measurement of the protein concentration by absorbance 
indicated that there was 0.5 mg protein in A14, which was stored as 100 µL aliquots in 
elution buffer at -80oC.  
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Figure 3.6 Purification of FGF-7. 
A.Bacteria from a 2 L culture were broken by sonication and loaded on a 3 ml column of 
Ni
2+ 
agarose. B. The 0.5 M imidazole eluate from Ni
2+
 column was buffer-exchanged and 
digested with TEV protease (Section 2.6.4). The digested proteins were applied again to the 
Ni
2+ 
 column, and the Ni
2+ 
 flow through was loaded to a 1 mL heparin column on an AKTA 
HPLC system (Section 3.2.1). Elution was monitored at 214 and 280 nm and peaks collected 
in 1 ml fractions. Fractions were analyzed by SDS-PAGE followed by comassie staining. 
The molecular weight FGF-7 with his tag is ~17 kDa. Pellets = insoluble material following 
cell breakage; Load = sample applied to Ni column; FT = flow through fraction; elution = 
imidazole eluate; digest overnight, product of TEV protease digest; Ni flow though = 
material not binding to Ni column after TEV digest; flow through = flow through after 
loading on heparin column; A14-B15, fractions eluted from HiTrap heparin column. 
3.2.2.4 Expression and purification of FGF-9 
3.2.2.4.1 Expression 
FGF-9 was found to be largely present (> 90 %) as insoluble proteins after IPTG induction, 
which suggests that most of the protein is in inclusion bodies. As an alternative, a self 
induction system, which uses medium containing sucrose to induce expression was 
employed (Section 2.5.2), to increase the proportion of soluble FGF-9. 
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3.2.2.4.2 Purification 
FGF-9 was produced using the plasmid described in Section 3.1.3.4 from a culture of 2 L 
(Section 3.2.1.2). To help protect the structure of FGF-9 and avoid unexpected degradation, 
a small amount of glycerol (5 %) and Tween 20 (0.2 %) and a tablet of protease inhibitor 
cocktail were added into the lysis buffer prior to the sonication step (Section 3.2.1.3). 
Lysozyme and DNase I were also added to increase cell breakage. 
The elute from the heparin affinity resin column (Section 3.2.1.4) was diluted and purified 
on a HiTrap 1 mL Ni column (Section 3.2.1.6). Twenty-two fractions were collected (A5-B5) 
corresponding to the protein peak. These fractions, along with samples corresponding to the 
starting material and unbound protein were analyzed by SDS-PAGE. The most obvious band, 
of ~26 kDa, was present pure in fractions A12 to B15 (Figure 3.7 B, C). Measurement of the 
protein concentration by absorbance indicated that there was 0.1-0.2 mg/mL protein in A12 
to B5, which was concentrated by spin column (5,000 MWCO, GE, Healthcare) to 1 mg/mL, 
and stored as 100 µL aliquots in elution buffer at -80oC.  
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Figure 3.7 Purification of FGF-9. 
A.Bacteria from a 2 L culture were broken by sonication and loaded on a 5 mL column of 
heparin agarose. B. The 2 M NaCl eluate from this column was diluted 4 times by 50 mM 
Tris.HCl, pH 7.5 and applied to a 1 mL HiTrap Ni column on an AKTA HPLC system 
(Section 3.2.1). Elution was monitored at 280 nm and peaks collected in 1 mL fractions. 
Fractions were analyzed by SDS-PAGE followed by Coomassie staining. The molecular 
weight of FGF-9 with its his tag is ~26 kDa. Pellets = insoluble material following cell 
breakage; Load = sample applied to heparin column; FT = flow through fraction; elution = 
NaCl elute; Ni flow though = flow through after loading on Ni column; A5-B5, fractions 
eluted from HiTrap Ni column. Fractions without other visible bands were concentrated and 
stored in -80
o
C. 
3.2.2.5 Expression and purification of FGF-18 
FGF-18 was produced using the plasmid described in Section 3.1.3.4 from a culture of 0.5 L 
(Section 3.2.1.2). The second flow through (after overnight digestion with TEV) from the 
Probond Ni
2+
 resin column (Section 3.2.1.5) was diluted and loaded on to a HPLC HiTrap 
heparin affinity column (Section 3.2.1.6). Four fractions were collected (B11-B8) 
corresponding to the major protein peak (Figure 3.8A). FGF-18 clearly requires far higher 
concentrations of NaCl for elution from heparin than FGF-1, FGF-2 or FGF-9. SDS-PAGE 
shows that the most obvious band, of ~21 kDa was present in fractions B11-B8 (Figure 3.8 
B). Measurement of the protein concentration by absorbance indicated that there was 0.3 mg 
protein in B10 and 0.2 mg in B9.  These two fractions were stored as 100 µL aliquots in 
elution buffer at -80oC. 
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Figure 3.8 Purification of FGF-18. 
A.Bacteria from a 2 L culture were broken by sonication and loaded on a 3 mL column of 
Ni
2+ 
agarose. B. The 0.5 M imidazole eluate from the Ni
2+
 column was buffer-exchanged into 
50 mM Tris-Cl, pH 7.5, 0.6 M NaCl and digested with TEV protease (Section 2.6.4). The 
digested proteins were applied again to the Ni
2+ 
 column and the flow through was loaded to 
a 1 mL heparin column on an AKTA HPLC system (Section 3.2.1). Elution was monitored 
at 280 nm and peaks collected in 1 mL fractions. Fractions were analyzed by SDS-PAGE 
followed by comassie staining. The molecular weight of FGF-18 is ~21 kDa. Pellets = 
insoluble material following cell breakage; Load = sample applied to heparin column; FT = 
flow through fraction; elution = NaCl elute; digest overnight = product of TEV protease 
digest;Ni flow though = material not binding to Ni column after TEV digest; Heparin flow 
through = flow through after loading on heparin column; B11-B8, fractions eluted from 
HiTrap heparin column. 
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3.2.2.6 Expression and purification of FGF-21 
3.2.2.6.1 Introduction 
The protein sample from cell breakage was purified on the Ni
2+
 Resin and Q column, 
because this endocrine FGF does not bind strongly to heparin, and according to FGF-21’s 
theoretical pI (5.78), it is acidic. So anion-ion exchange chromatography was used after Ni 
chelation to further purify FGF-21.  
3.2.2.6.2 Purification 
FGF-21 was produced using an existing plasmid described in Section 3.1.3.4 from a culture 
of 0.5 L (Section 3.2.1.2) The elute from the Probond Ni
2+
 resin column (Section 3.2.1.5) 
was diluted and loaded on to a HPLC Q column 1 mL column (Section 3.2.1.6). Eight 
fractions were collected (A10-B14) corresponding to the major protein peak. These fractions 
were analyzed by SDS-PAGE (Figure 3.9B). The result shows that the most obvious band, 
of ~25 kDa, was present in the fractions. Measurement of the protein concentration by 
absorbance indicated that there were 0.6 mg protein in A12, 1.06 mg in A13 and 0.91 mg in 
A14. These three fractions were stored in buffer B at -80oC.  
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Figure 3.9 Purification of FGF-21. 
A.Bacteria from a 0.5 L culture were broken by sonication and loaded on a 3 mL column of 
Ni
2+ 
agarose. B. The 0.5 M imidazole eluate from this column was buffer- exchanged into 50 
mM Tris-Cl, pH 7.5 and applied to a 1 mL Q column on an AKTA HPLC system (Section 
3.2.1). Elution was monitored at 280 nm and peaks collected in 1 mL fractions. Fractions 
were analyzed by SDS-PAGE followed by Comassie staining. The molecular weight FGF-21 
with a his tag is ~25 kDa. Pellets = insoluble material following cell breakage; Load = 
sample applied to heparin column; FT = flow through fraction; Elution = NaCl elute; 2
ND
 FT 
= flow through after loading on Q column; A10-B14, fractions eluted from HiTrap heparin 
column. 
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3.2.3 Expression of other FGFs (FGF-3, FGF-5, FGF-16, FGF-17, FGF-
19 & FGF-23) 
FGF-19 and FGF-23 plasmids were transformed into different E.coli cells (C41, T1, RG 
(blue) and Rosetta) using different antibiotics, according to the requirement of the different 
cells] and protein was expressed from a culture of 0.1 L following the protocol used for 
FGF-1 (Section 3.2.1.2). Induction was at 37oC for 3 h as for FGF-1 (Section 3.2.1.2). The 
products from 100 mL culture were then subjected to purification on Ni
2+
 chelation columns. 
There was no evidence for elution of a protein corresponding to these FGFs. SDS-PAGE 
showed that there was a band of the correct size, but it was in the cell pellets, so these 
proteins are not soluble.  
3.3 Different FGF stimulations of DNA synthesis on Rama 27 
cells 
3.3.1 Introduction 
As growth factors, FGFs have been found to induce the stimulation of a number of 
intracellular signaling pathways that lead to cell division. In these experiments, cells were 
treated with 10 % (v/v) FCS as a positive control for the stimulation of DNA synthesis. The 
stimulation of DNA synthesis by six different FGFs (FGF-1, FGF-2, FGF-7, FGF-9, FGF-18 
and FGF-21) with and without heparin was tested in Rama 27 fibroblast cells.  
3.3.2 Results 
Different concentrations of six FGFs were added to quiescent Rama 27 cells to determine 
and compare the dependence of DNA synthesis on the growth factors (Section 2.8).  
In the case of FGF-1, an increase of DNA synthesis occurred between concentrations 1 to 30 
ng/mL (Fig. 3.10A). When 5 µg/mL heparin was present, the FGF-1 starts stimulation at a 
lower concentration (0.1 ng/ml), since a stimulation of DNA synthesis reached a maximum 
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at 3 ng/mL (Figs 3.10A). This is in accord with previous results, which showed that heparin 
can stabilize FGF-1 and increase its activity in such assays [108-110]. 
For FGF-2, an increase of the stimulation started at 0.1 ng/mL, so similar to FGF-1 in the 
presence of heparin (Fig. 3.10B) and reached a maximum at 1 ng/mL. 
For FGF-9, an increase of the stimulation was apparent from 15.4 ng/mL (Fig.3.11A) and 
continued increase up to 15,400 ng/mL. Heparin (5 µg/mL) had no effect on the stimulation 
of DNA synthesis by FGF-9 in these cells (Figs 3.11A).  
FGF-18 has an effect on DNA synthesis only between the concentrations of 140 ng/mL to 
1,400 ng/mL (Fig.3.11B). In contrast, when heparin was present, the stimulation of DNA 
synthesis started from a lower concentration, 14 ng/mL, and reached a maximum at 1,400 
ng/mL (Figs 3.11B).  
For FGF-7 and FGF-21, there was no measurable change induced by these FGFs (FGF-7: 
27300 ng/mL, FGF-21: 12000 ng/mL) (Fig.3.12) and no effect of heparin.  
Taken together, different FGFs have different stimulation on Roma 27 cells. FGF-2 starts to 
have signal at lower levels compared to other FGFs.  Heparin (5 µg/mL) increases the 
potency of FGF-1 to stimulate DNA synthesis from a lower level than FGF-1 itself, and 
heparin also help with FGF-18 to stimulate the cells from a lower level, but heparin had no 
such effect on FGF-18. 
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Figure 3.10 Concentration dependence of the stimulation of DNA synthesis in Rama 27 
cells by FGF-1 and FGF-2. 
The experiment was carried out as described in Method 2.8. A. FGF-1 with and without 5 
µg/mL heparin. B. FGF-2. Results are expressed as the mean cmp±SD of triplicate samples. 
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Figure 3.11 Concentration dependence of the stimulation of DNA synthesis in Rama 27 
cells by FGF-9 and FGF-18. 
The experiment was carried out as described in Section 2.8. A. FGF-1 with and without 5 
µg/mL heparin. B. FGF-2. Results are expressed as the mean cmp±SD of triplicate samples.  
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Figure 3.12 The stimulation of DNA synthesis in Rama 27 cells by FGF-7 and FGF-21. 
The experiment was carried out as described in Section 2.8. A. FGF-1 with and without 5 
µg/mL heparin. B. FGF-2. Results are expressed as the mean cmp±SD of triplicate samples.  
3.3.3 Discussion 
The DNA synthesis experiment was used to test the activity of six recombinant FGFs (FGF-
1, FGF-2, FGF-7, FGF-18 and FGF-21) in Rama 27 cells. Rama 27 cells are fibroblasts and 
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have been shown by PCR to express FGFR1c as the two and three Ig loop isoforms [96]; 
(Chen and Fernig, unpublished).  They are, therefore, typical of a stromal cell in this respect. 
The dose-dependence of FGF-2, which started to stimulate the cells' DNA synthesis at 0.1 
ng/mL and reached the maximal level at 1 ng/mL, is in agreement with previous results on 
these cells obtained with natural FGF-2, purified from cow pituitary [111]. The lower 
potency of FGF-1 is also in agreement with previous results with these cells [108].  
Moreover, the increased potency of FGF-1 observed in the presence of heparin has been 
noted for many years [108-110]. Though both FGF-9 and FGF-18 stimulated DNA synthesis 
in these cells, they were far less potent compared to FGF-1 and FGF-2. At a concentration of 
3 ng/mL, stimulation of incorporation of [
3
H] thymidine into DNA synthesis of FGF-1 
reached its 50 % effective dose (ED50), which is 12 times higher than that needed by FGF-2 
(ED50: 0.25 ng/mL). FGF-18 reached a half maximum (ED50) at a concentration of 220 
ng/mL, which is about 70-fold above that of FGF-1. In contrast, the stimulation of DNA 
synthesis by FGF-9 was still increasing at 15.4 µg/mL, which is 500-fold more than the 
concentration of FGF-1 required for maximal DNA synthesis. The reason for the 
considerable lower potency of FGF-9 and of FGF-18 may be related to the weak activity of 
these two FGFs with FGFR1c compared to the FGF-1 sub-family [46], because the R27 cells 
only have the FGFR1c. 
The lack of activity of FGF-7 is not surprising, since this FGF is uniquely specific for 
epithelial cells, which express the FGFR2c splice variant. mRNA encoding FGFR2c is not 
detected in stromal cells such as Rama 27 fibroblasts (Chen and Fernig, unpublished). For 
FGF-21, a previous study showed that FGF-21 only has weak FGFR stimulatory activity [46] 
and it is a hormone, regulating glucose metabolism, so that it is not surprising that it does not 
detectably stimulate DNA synthesis. 
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3.4 Discussion 
Recombinant FGFs (FGF-1, FGF-2, FGF-7, FGF-9, FGF-18 and FGF-21) were expressed 
using E. coli system, and purified by affinity chromatography and ion-exchange 
chromatography, ~ 1 to 10 mg pure proteins (no substantial contaminants or SDS-PAGE) 
were achieved (according to concentration measurement) for each FGF. That these FGFs are 
correctly folded is indicated by the observation that they bind heparin (all except FGF-21) 
and that all the FGFs were able to activate FGFR1c in DNA synthesis assays. Thus, good 
coverage of the FGF sub-families that are extracellular (Figure 1.1) was achieved, with at 
least one FGF ligand produced from FGF sub-families 1, 7, 8, 9 and 19, and only a 
representative from sub-family FGF-4 missing 
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Chapter 4 Diversification of the structural 
determinants of FGF-heparin interactions 
4.1 Introduction 
It is a major question whether there are specificities in the interactions between HS/heparin 
and FGFs. It is accepted that HS/heparin are essential for FGF ligands to engage the FGFR 
and generate signals that lead to cell division. In vivo it is also clear that the polysaccharide 
is critical for FGF signaling activity in development (Section 1.8). There is evidence that 
shows that the FGF:HS:FGFR interactions require specific structures in the sugar [91, 112]. 
However, the details of such specificity are not clear.  Thus, DP8 has been shown to be the 
minimal length of heparin sugars to allow FGF-1 and FGF-2 to bind FGFR1 or FGFR2 and 
6-O-sulfate was similarly shown to be essential to allow receptor dimerization [93]. However, 
other studies have shown that smaller oligosaccharides are effective for FGF-2 [57]. Finally, 
a series of studies suggest that the binary FGF:heparin interactions are very promiscuous and 
failed to identify any real specificities [97-99]. According to this view different FGFs bind to 
HS-derived oligosaccharides with similar relative affinities and low selectivity, such that the 
strength of these interactions increases largely due to the overall level of sulfation rather than 
other characteristics [97] and that different members of the FGF family share the same 
binding sites on the HS chains [98, 99]. One weakness of this previous body of work is that 
it is piecemeal; interactions are often measured qualitatively and, in many instances, in a 
format in which ionic bonding will predominate. The problems associated with measuring 
protein-heparin interactions were reviewed some eight years ago [27]. 
To try to resolve the question of specificity, this study has focused on using several 
complementary methods to study the interactions of FGFs with heparin and allied molecules.  
In addition, by using a panel of FGFs from different sub-families, any constraints on 
specificity related to the evolution of the FGF family should also become apparent. 
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Consequently, several methods were applied to characterize the interaction of the panel of 
FGFs with heparin.  
MST and optical biosensor-: two methods which were used to quantify the binding kinetics 
and/or affinity of FGFs to an octasaccharide derived from heparin. These techniques, by 
measuring fundamental physical parameters, are not prone to biases of interpretation 
associated with qualitative methods used in some other studies. 
Protect & Label-: a strategy used to identify the binding sites in FGFs of heparin. This 
would provide a "mirror" to the work on sugars; differences in binding sites in the proteins 
might be reflected in some way in differences in binding specificity and/or affinity. 
SRCD-: a method which measures the secondary structure of FGFs and their sugar 
complexes, to test whether there are conformational changes in FGF ligands after binding to 
heparin.  
DSF-: measures the thermal stabilizing effect on FGF ligands when they bind to heparin.  
Since DSF is a solution technique of high throughput, the interactions of FGFs with a library 
of sugars could be determined.  This allowed questions of specificity relating to the length of 
sugar binding site, sulfation patterns and cation forms of heparin to be measured.  
The results of this work have been submitted for publication at the Journal of Biological 
Chemistry and the manuscript is appended below. 
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4.2 Paper  
 
 
 
 
Contributions of the authors 
Xu, R.: Production of FGF proteins, DSF, Protect and Label, SRCD and biosensor 
measurements.  co-wrote the paper. 
Ori, A.: Mass spectrometry of biotinylated peptides.  Edited paper. 
Rudd, T.R.: PCA. Edited paper. 
Uniewicz, K.A.: Some DSF experiments (repeated by RX) and help with cloning of FGF-18 
and protect and label experments.  Edited paper. 
Ahmed, Y.A.: Oligosaccharides of DP2 to DP12.  Edited paper. 
Guimond, S.E.: Assisted with SRCD experiments.  Edited paper. 
Skidmore, M.A.: Assisted with SRCD experiments.  Edited paper. 
Siligardi, G.: SRCD beamline manager, assisted with SRCD experiments and their 
interpretation.  Edited paper. 
Yates, E.A.: Provided heparin derivatives, conceived study and co-wrote the paper. 
Fernig, D.G.: Conceived study and co-wrote the paper. 
This text box is where the unabridged thesis included the following third party copyrighted 
material: 
Xu, R., Ori, A., Rudd, T.R., Uniewicz, K.A.,Ahmed, Y.A., Guimond, S.E., Skidmore, 
M.A., Siligardi, G., Yates, E.A. and Fernig, D.G. (2012) Diversification of the structural 
determinants of fibroblast growth factor-heparin interactions; implications for binding 
specificity. J. Biol. Chem. 287:40061-40073. 
http://www.jbc.org/content/287/47/40061.long 
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4.3 DSF 
4.3.1 DSF and heparin-dependent thermostabilizing effects on FGFs 
DSF was used to determine the melting temperature of six different FGFs (FGF-1, FGF-2, 
FGF-7, FGF-9, FGF-18 and FGF-21) and their sugar complexes. The FGF-1, FGF-2 and 
FGF-18 data shown below are repeat experiments of the previous publication [102], and the 
FGF-7, FGF-9 and FGF-21 data are from the paper above. The ligand melting temperatures 
were sharp, indicating that these FGFs were properly folded and spanned 12oC (Figures 4.1-
4.3; Figure 7 and Figures S11-13 in Section 4.2), suggesting that the different FGFs have 
different rigidities and thermal stabilities. A concentration range from 0.05 µM to 500 µM of 
heparin with these six FGFs was also measured by DSF. The addition of heparin caused an 
increase in melting temperature in all the FGFs, except for FGF-21 (Figures 4.1-4.3; Figure 
7 and Figures S11-13 in Section 4.2).  
The effect of heparin on FGF-1, FGF-2 and FGF-18 agreed with a previous study [102], in 
which heparin has a concentration dependent effect on the melting temperature of these 
FGFs. FGF-1 TM increased about 7 degrees in the presence of 1.25 µM heparin, which then 
increased another 14 degrees as the concentration of heparin increased to 500 µM (Figure 
4.1). When heparin was added to 5 µM FGF-2, the melting temperature of FGF-2 increased 
in a dose–dependent manner (Figure 4.2). The TM of FGF-2 also started increasing from 
1.25 µM heparin, and reached the highest level at 25 µM heparin, to 80oC.  Like FGF-1, the 
TM of FGF-7 also started increasing with 1.25 µM heparin and quickly reached a maximum 
at 5 µM heparin. In contrast, FGF-7 was stabilized to a lower extent than FGF-1 and FGF-2, 
since when it bound heparin there was only a 7oC increase in melting temperature. Maximum 
stabilization was achieved at relatively low concentrations of heparin (5 μM). In contrast, the 
TM of FGF-9 started increasing at a lower heparin concentration (0.05 µM), and continued to 
increase until 2.5 µM (Figure S11 in Section 4.2). FGF-18 was progressively stabilized 
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from the lowest concentration of heparin and maximum stabilization had not been reached at 
500 μM heparin (Figure 4.3). 
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Figure 4.1 Stabilization effect of heparin on FGF-1. 
Differential scanning fluorimetry of 5 µM FGF-1 in the presence of different concentrations 
of heparin (Section 2.9): A, Melting curve profiles of FGF-1 (5 µM) with a range of heparin 
concentrations (0 µM-500 µM). B, The first derivative of the melting curves in (A). C, Peak 
of the first derivative of the melting curves from (B), which is the melting temperature, TM 
(mean of triplicates +/- SE). 
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Figure 4.2 Stabilization effect of heparin on FGF-2. 
Differential scanning fluorimetry of 5 µM FGF-2 in the presence of different concentrations 
of heparin (Section 2.9): A, Melting curve profiles of FGF-2 (5 µM) with a range of heparin 
concentrations (0 µM-500 µM). B, The first derivative of the melting curves in (A). C, Peak 
of the first derivative of the melting curves from (B), which is the melting temperature, TM 
(mean of triplicates +/- SE). 
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Figure 4.3 Stabilization effect of heparin on FGF-18. 
Differential scanning fluorimetry of 10 µM FGF-18 in the presence of different 
concentrations of heparin (Section 2.9): A, Melting curve profiles of FGF-18 (10 µM) with a 
range of heparin concentrations (0 µM-500 µM). B, The first derivative of the melting curves 
in (A). C, Peak of the first derivative of the melting curves from (B), which is the melting 
temperature, TM (mean of triplicates +/- SE). 
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4.3.2 Characterization of the thermo stabilizing effect of different 
polysaccharides on FGFs 
A heparin library of sugars was tested against a fixed concentration (5 µM or 10 µM) of 5 
FGFs (FGF-1, FGF-2, FGF-7, FGF-9 and FGF-18), which belong to 4 different sub-families 
(FGF-1 sub-family, FGF-7 sub-family, FGF-9 sub-family and FGF-8 sub-family) to identity 
the variety of the sugars binding to FGFs (Fig. 4.4).   
To understand the different binding effect of different sulfation pattern of heparin, D1-D9 
were tested against these 5 different FGFs (Fig. 4.4A). FGF-1 was sensitive to the loss of 
any sulfate group, though it appeared to have a preference for 2S over the two O-sulfates. 
Loss of two or more sulfates caused a loss of interaction. With singly desulfated heparins, 
FGF-2 clearly required 2S and NS, but not 6S for strong binding. Loss of two or more 
sulfates abrogated binding. This is quite similar to FGF-1. FGF-7 appeared to bind 
derivatives equally well with any pair of sulfates, losing about 20-30 % of heparin binding 
affinity, but less than two sulfates reduced binding appreciably. With loss of any one sulfate, 
FGF-9 lost about 50 % binding affinity compared to intact to heparin. Loss of 2 or more 
sulfates reduced binding to just 10-20 % of the original level. For FGF-18, somewhat lower 
binding was achieved with any two sulfates. Losing two sulfates decreased heparin binding 
further and 2S alone was less effective than either 6S or NS.  
To understand the different binding effect of length heparin, oligosaccharides from DP2 to 
DP12 were tested against these 5 different FGFs (Fig. 4.4B). FGF-1 had a weak interaction 
with DP2 and this progressively increased to reach a maximum with DP8.  Analysis of data 
acquired with heparin oligosaccharides of different lengths showed that DP2 did not bind 
FGF-2, whereas DP4 bound and further increasing the oligosaccharide length to DP12 
resulted in a progressive increase in the thermal stability of FGF-2. FGF-7 bound DP4 and it 
was maximally stabilized by DP8, which had about 50 % of the stabilization effect of 
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heparin. In contrast, FGF-9 started binding from DP4, but required longer oligosaccharides, 
DP10 achieving the maximum effect. FGF-18 bound DP2, but its thermal stability was 
enhanced by larger structures up to DP12. Other GAGs (HS, HA, CS and DS were also 
tested (Fig. 4.4C). HS has a similar effect on FGF-1, FGF-2 and FGF-7, which is only half 
of the binding affinity compared to heparin. FGF-9 and FGF-18 are similar, only about 30 % 
of heparin binding. Only FGF-18 had 20 % binding to HA, others did not bind. FGF-2 failed 
to interact with CS or DS, whereas the other FGFs showed possible weak interaction with 
CS and a weak, but significant, interaction with DS. 
Cation modified heparins (Na
+
, K
+
, Ca
2+
, Cu
2+
 and Zn
2+
) were also tested with these five 
FGFs (Fig. 3.19D). Different cationic forms bind FGF-1 differently, Na
+
, K
+
 and Ca
2+
 had 
similar effects on binding, which reduced binding slightly, to ~ 80 % of the level observed 
with heparin. In contrast, FGF-1 bound very poorly to the Zn
2+ 
form of heparin. In the 
presence of Cu
2+
 heparin, no melting curve was apparent, suggesting that FGF-1 cannot 
interact with this form of heparin. In contrast, these five cationic forms of heparin all bound 
FGF-2 similarly, causing a small (10 %) increase in stabilization compared to native heparin. 
FGF-7 binding was reduced by all the cationic forms of heparin compared to that observed 
with native heparin; by ~30 % with Na
+
, K
+
, Ca
2+
 and Zn
2+
 heparin and by 80 % with Cu
2+
 
heparin. In contrast, the different cationic forms of heparin all bound FGF-9 equally, causing 
a 30 % reduction in thermal stabilization. FGF-18 binds better to the Zn
2+
 form of heparin 
than to heparin itself. However, the Na
+
 form heparin only has half the affinity when bound 
to FGF-18 compared to heparin, and the other three cationic forms of heparin have similar 
effects on FGF-18 binding, causing a 10-20 % decrease in thermal stabilization.  
Most of the data here for FGF-1, FGF-2 and FGF-18 are in agreement with a previous study, 
except that FGF-18 was previously observed to start  binding from DP6 [102]. However, the 
data in previous publication are quite noisy for DP2 and DP4, and it is possible that weak 
binding to these smaller oligosaccharides may have been obscured. 
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Figure 4.4 Differential scanning fluorimetry analysis of heparin derivatives on FGF-7 
and FGF-9 reveals distinct dependency on substitution pattern. 
Differential scanning fluorimetry was performed with a range of heparin-based poly- and 
oligosaccharides with 5 µM protein and 175 µg/mL sugar. The relative thermal stabilization 
effect of: A. Controls (PBS and heparin), chemically modified heparins (D2-D9). B. 
Heparin-derived oligosaccharides, ranging from DP2-12. C. Other GAGs (HS, HA, CS and 
DS). D. Cation modified heparin forms [113]. Results are the mean of triplicates after 
normalisation +/- SE, an apparent absence of error bar is due to a small SE). 
4.4 Discussion 
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The specificities of FGF-heparin interactions are clearly revealed by all these methods: 
kinetic parameters and affinity measurements clearly showed differences in binding; Protect 
and Label showed that the binding for the polysaccharide in the FGFs employs different 
combinations of amino acids at the different positions on the surfaces of the FGFs; SRCD 
data showed that FGFs have different conformational changes when bound to heparin; DSF 
screening against sugar libraries results showed that they have different binding selectivity to 
the sugar chains and sulfation patterns. However, the specificity does not correspond to a 
high fidelity 1:1 binding. Instead, FGFs have preferences, but can recognize a wide range of 
sites in the sugar.   
4.4.1 Multiple specificities 
DSF and principle component analysis (PCA):- The PCA was carried out by Dr Tim Rudd, 
DSF analysis of binding of the six FGFs (FGF-1, FGF-2, FGF-7, FGF-9, FGF-18 and FGF-
21) to the sugar library clearly showed that there are binding preferences between FGFs and 
heparin. However, the relationships were complex, so a PCA was used to identify the main 
components contributing to the specificity of interaction. The PCA clearly shows that the 
FGFs are different, but does not identify a single component, e.g., N-sulfation.  This 
highlights that specificity of interaction is due to the interaction of a number of contributing 
elements, e.g., sulfation pattern, length, which are not necessarily separable.  
Thus, the binding specificities of FGFs to heparin/HS exhibit multiple specificities, which 
means the binding does not only rely on one structure pattern, but instead is much more 
reliant on the whole structure. The current analysis can only report on the sequence of 
saccharides, rather than their conformation, but the two are interdependent.  Thus, though not 
tested here, this points to specificity relying on the solution conformation of the sugar chains.  
4.4.2 Heparin binding sites overlapped with FGFR binding sites 
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FGF mediate their bioactivities by binding to their cell surface receptors FGFR and HS to 
form a signaling complex.  It seems likely that in vivo FGF binds first to HS first then to the 
FGFR, since HS binding sites are several orders of magnitude more abundant in the 
pericellular matrix and cell surface (Duchesne et al. 2012) [114]. According to the present 
results there are different numbers of HBSs found in these 4 FGF sub-families. A question is 
of interest is whether there is any overlap between these and the FGFR binding sites.  
FGF-2 has 3 heparin binding sites [49, 75, 88, 115, 116], and the residues interacting with 
the FGFR have been identified by site-directed mutagenesis [50] and by X-ray 
crystallography (FGF-2-FGFR1, PDB: 1CVS) [51]. A comparison of these binding sites 
indicates that HBS-3 at the N-terminus overlaps with the FGFR binding site at position K30.   
As well as FGF-2, others FGFs also have residues involved in both interactions. According 
to the Protect and Label results and crystal structures of heparin-FGF-1-FGFR2 (PDB: 1E0O) 
[53], in FGF-1, K24 in HBS-3 overlaps with the FGFR binding site.  K24 in FGF-1, which is 
located at N-terminus of the protein, is at the equivalent position as K30 of FGF-2 when the 
secondary structures of these proteins are aligned (Figure 2A in Section 4.2).  
According to the sequence alignment of FGF-7 (Figure 2B in Section 4.2), there might be a 
HBS-3 at the N-terminus, but because this only contains arginines, which cannot be 
identified by Protect and Label it was not identified here. Interestingly, R65 in the putative 
FGF-7 HBS-3 is also a part of its FGFR [117]. Moreover, by using the sequence alignment 
of the FGF-7 subfamily and the FGF-10-FGFR2b crystal structure (PDB: 1NUN) [23], R78 
of FGF-10, which is at the equivalent position as R65 in FGF-7 might be part of a HBS-3 
(Figure 2C in Section 4.2) and is involved in binding to FGFR. 
The HBSs of FGF-8 were predicted by the sequence alignment of the FGF-8 subfamily 
(Figure 2D in Section 4.2), while the FGFR binding sites for this FGF was reported in the 
FGF-8b-FGFR2c crystal structure (PDB: 2FDB) [24].  There are two positions of HBS-2 
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that overlap with the FGFR binding site, one is between beta strand 12 and the C-terminus 
(
196-
KRLPR
-200
), the other one is R27, which is at the same position as the HBS-3 of FGF-2 
(Figure  in Section 4.2).  
HBS-1 is of higher affinity that HBS-3, in the only instance where this has been measured 
[115].  However, on a cell, the concentration of HS binding sites is high.  Moreover, at least 
for FGF-2, though it may dissociate locally from cellular HS, it rebinds very rapidly, such 
that it does not, in a cell culture, dissociate in the bulk culture medium.  Thus, all the HBS of 
and FGF are likely, at some point, to interact with HS on the cells surface. Given that the 
HBSs seem to be conserved within FGF subfamilies, they seem likely to have a collective 
role that has been selected for in the course of evolution. This points to a role for the overlap 
of the HBS-3 of these five FGFs with their FGFR binding site. HBS-3 may have a role in 
transferring the binding in the FGF signaling complex: in which HS engaged to the HBS-3 of 
the FGF, guides the HBS-3 of the FGF binding to FGFR. Due to the weaker binding of HBS-
3, this may help the transfer. The part of HBS-2 of FGF-8, which is located between beta 12 
and C-terminal is merged together with HBS-3 in the 3-D structure of the protein and so may 
also have a similar effect as HBS-3. 
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Chapter 5 SRCD: Circular dichroism 
spectroscopy reveals distinct secondary 
structures among FGF sub-family members. 
5.1 Introduction 
To determine the secondary structural changes of six different FGFs when binding to heparin, 
the purpose built SRCD beamline B-23 at the Diamond Synchrotron was used. Circular 
dichroism (CD) is a method which is widely used for examining protein secondary structure 
characteristics and protein-protein interactions [115-117]. CD is a spectroscopic method that 
measures  the  differential  absorption  of  left  and  right  circularly  polarized  light  by 
chiral molecules.  In the case of proteins, CD is very sensitive method for the detection of 
secondary structures [118, 119].  
Owing  to  characteristic geometry, each protein secondary structure type has a characteristic 
CD spectrum, e.g., the typical  α-helix  spectrum  contains  a  large  positive  peak  at  ~192  
nm,  another positive peak of roughly half of the magnitude at around 208 nm, and a 
negative peak at ~222 nm. For β-sheet, there is a negative peak at ~198, which is about half 
of the helix magnitude, and a small negative peak at ~215 nm. Turns and disorders structure 
do not have specific spectral features. 
The dextrorotary and levorotary components within protein structures will give different 
absorptions. The amide group of the peptide chain is the most consequential chromophore of 
proteins [118]. The far UV region of a CD spectrum (180-260 nm) is related to the peptide 
backbone chromophore transitions (n → π* and π → π*). 
Because of the position and intensity of all these transitions, it causes different secondary 
structures of proteins giving rise to different far-UV spectra, e.g. the negative peak at ~222 
nm of α-helix and the one of β-sheet at ~215 are the n → π* transition; the positive peaks of 
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α-helix at ~192 nm and ~208 nm and the negative peak of β-sheet at ~198 are caused by π → 
π* transitions [118, 119]. 
Then,  by  analyzing  the  CD  spectra,  it  is  possible  to  estimate  the  secondary  structures  
(α-helices, β-sheets, turns and disorders) for each protein. SRCD provides intense 
synchrotron light, with 10
3
-10
4
 fold greater photon flux than normal CD.  Also, the heparin 
itself were measured by SRCD, it only have a very little signals, which is because of heparin 
chains are loose helix structure [120], which would not give a strong signal. 
5.2 Methods 
Six different FGFs (FGF-1, FGF-2, FGF-7, FGF-9, FGF-18 and FGF-21) at concentration of 
0.5 mg/ml (FGF-1, FGF-2, FGF-7, FGF-18 and FGF-21) or 1 mg/mL (FGF-9) and their 
heparin complexes at different molar ratios at 1:5, 1:1 and 5:1 (heparin: FGF, w/w) were 
measured by SRCD (Section 2.12). Also, different FGFs were tested with several different 
chemically modified heparins at 1:1 molar ratio: FGF-1 with D8, FGF-2 with D4 or D6, 
FGF-7 with D2 or D8, FGF-9 with D7 and FGF-18 with D6. 
5.3 Results 
SRCD was used explore the structural changes of FGFs and their sugar complexes. The 
SRCD spectra of the protein constructs of six FGFs and their heparin complexes were 
collected under the same conditions (Figure 5.1) (Section 2.12) and the spectra were 
analysed using SELCON3 and Database 3 (Section 2.12). FGFs and their 5:1 (heparin: FGF) 
complexes were used for the work in the publication (Chapter 4). The spectrum of FGF-18 
exhibited significant changes when heparin was introduced, while FGF-1, FGF-2 and FGF-7 
also showed some visible changes (Figure 5.1 A-D and Table 5.1-5.4). The spectra of FGF-
1 showed that, as more heparin was introduced, the signals of FGF-1 became more linear, 
however, the FGF-9 spectra became less flat. In contrast, the spectra of other FGF heparin 
SRCD: Circular dichroism spectroscopy reveals distinct secondary structures among  
FGF sub-family members 
 
132 
 
complexes were not concentration dependent (Figure 5.1). According to analysis using 
SELCON 3, when 1:5 or 5:1 (F:H) molar ratios of heparin were added to FGF-1, the 
spectrum exhibited more α-helix, while, for a 1:1 (F:H) molar ratio of heparin, the spectra 
were more disordered (Table 5.1). As more heparin was added to FGF-2 and FGF-18, the 
signal progressively increased until a protein sugar ratio of 1:1, where the spectra are quite 
similar to those of the protein alone (Figure 5.1B and E, Table 5.1 and 5.5). With a 5:1 
(F:H) molar ratio, FGF-7 started to exhibit more helix, whereas, when the molar ratio 
changed to 1:1 (F:H), the FGF-7 spectrum changed from α-helix to β, and when heparin 
levels continued to increase to a 1:5 (F:H) ratio, the structure returned to resemble as FGF-7 
itself (Figure 5.1 C, Table 5.3). Taken together, there was not a simple trend of structural 
changes when the heparin concentration increased in the system. However, the spectrum of 
FGF-9 was only partly affected; the changes only started with higher concentrations at molar 
ratio 1:5 (F:H) (Figure 5.1 D and Table 5.4) and FGF-21 was largely unaffected (Figure 
5.1 F and Table 5.6). The small change seen with FGF-21 agrees with previous studies, 
confirming that FGF-21 binds to heparin only weakly, and is further corroborated by the lack 
of change in the DSF data (Figure 5.1F).  
Almost no change in the FGF-21 spectrum before or after the addition of heparin showed 
that heparin had almost no effect on the absorbance, indicating that this method is suitable 
for measuring the effect of heparin on FGFs structure. 
Several chemically modified heparins were also tested by this method. Chemically modified 
heparins have less effect on FGFs than heparin. There are no major changes between FGFs 
alone and when bound to these modified heparins for FGF-1, FGF-2 and FGF-7 (FGF-1 with 
D8, FGF-2 with D4 and D6 and FGF-7 with D8) (Figure 5.1). In contrast, FGF-9 with D7 
and FGF-18 with D6 showed considerable changes. However, they provide only limited 
information; confirming that modified heparins can also induce conformational changes 
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when binding to FGF, and indicating that the sulfation pattern is important for FGF-heparin 
interactions.
 
Figure 5.1 SRCD spectra of FGFs with different concentrations of heparin at molar 
ratios 1:5, 1:1 and 5:1, and with selected chemically modified heparins. 
A, FGF-1 with heparin and D8. B, FGF-2 with heparin, D4 and D6. C, FGF-7 with heparin, 
D2 and D8. D, FGF-9 with heparin and D7. E, FGF-18 with heparin and D6. F, FGF-21 with 
heparin. 
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Table 5.1 Secondary structure analysis of SRCD spectra of FGF-1 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns Unordered Total 
FGF-1  -0.001 0.027 0.293 0.195 0.228 0.250  0.993 
1:5 (H:F)  0.053 0.082 0.211 0.111 0.211 0.337  1.006 
1:1(H:F)  0.000 0.001 0.016 0.096 0.285 0.611  1.009 
5:1 (H:F)  0.053 0.083 0.211 0.111 0.211 0.339  1.009 
1:1 (F:D8)  0.053 0.082 0.211 0.111 0.211 0.336  1.003 
SRCD spectra of the FGF-1 alone, in the presence of molar ratios of heparin or with molar 
ratio 1:1 D8 were analyzed using SELCON 3 (Section 2.12 and 5.2).   
 
 
Table 5.2 Secondary structure analysis of SRCD spectra of FGF-2 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns  Unordered Total 
FGF-2   0.000 0.018 0.247 0.118 0.297 0.314 0.994 
1:5 (H:F)   0.421 0.245 0.051 0.038 0.117 0.136 1.009 
1:1 (H:F)   -0.001 -0.001 0.014 0.096 0.285 0.610 1.003 
5:1 (H:F)   0.000 0.000 0.015 0.096 0.285 0.610 1.006 
1:1 (F:D4)   0.000 0.028 0.294 0.196 0.229 0.252 0.998 
1:1 (F:D6)   0.000 0.028 0.294 0.197 0.230 0.253 1.003 
SRCD spectra of the FGF-2 alone, in the presence of molar ratios of heparin or with molar 
ratio 1:1 D4 and D6 were analyzed using SELCON 3 (Section 2.12 and 5.2).   
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Table 5.3 Secondary structure analysis of SRCD spectra of FGF-7 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns  Unordered Total 
FGF-7   0.211 0.136 0.043 0.067 0.231 0.314 1.001 
1:5 (H:F)   0.582 0.222 -0.001 -0.001 0.050 0.143 0.995 
1:1(H:F)   0.007 0.087 0.298 0.161 0.109 0.340 1.001 
5:1 (H:F)   0.001 0.000 0.012 0.094 0.284 0.608 0.999 
1:1 (F:D2)   0.214 0.194 0.000 0.000 0.234 0.361 1.004 
1:1 (F:D8)   0.215 0.195 0.001 0.000 0.234 0.362 1.006 
SRCD spectra of the FGF-7 alone, in the presence of molar ratios of heparin or with molar 
ratio 1:1 D8 were analyzed using SELCON 3 (Section 2.12 and 5.2).   
 
 
Table 5.4 Secondary structure analysis of SRCD spectra of FGF-9 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns  Unordered Total 
FGF-9 0.536 0.223 0.000 0.000 0.107 0.138 1.005 
1:5 (H:F) 0.536 0.224 0.002 0.001 0.107 0.139 1.010 
1:1 (H:F) 0.536 0.223 0.001 0.001 0.107 0.139 1.006 
5:1 (H:F) 0.210 0.136 0.044 0.068 0.233 0.316 1.006 
1:1 (F:D7) 0.000 0.000 0.016 0.097 0.286 0.611 1.011 
SRCD spectra of the FGF-9 alone, in the presence of molar ratios of heparin or with molar 
ratio 1:1 D7 were analyzed using SELCON 3 (Section 2.12 and 5.2).   
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Table 5.5 Secondary structure analysis of SRCD spectra of FGF-18 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns  Unordered Total 
FGF-18  0.000 0.000 0.015 0.095 0.285 0.609 1.004  
1:5 (H:F)  0.215 0.195 0.001 0.001 0.233 0.361 1.005 
1:1 (H:F)  0.006 0.087 0.299 0.161 0.110 0.340 1.003 
5:1 (H:F)  0.054 0.083 0.211 0.110 0.212 0.335 1.004  
1:1 (F:D6)  0.215 0.195 0.001 0.001 0.233 0.361 1.005 
SRCD spectra of the FGF-18 alone, in the presence of molar ratios of heparin or with molar 
ratio 1:1 D6 were analyzed using SELCON 3 (Section 2.12 and 5.2).   
 
 
Table 5.6 Secondary structure analysis of SRCD spectra of FGF-21 and heparin. 
Sample  Helix1 Helix2 Strand1 Strand2 Turns  Unordered Total 
FGF-21  0.421 0.245 0.051 0.038 0.117 0.136 1.008 
1:5 (H:F)  0.422 0.246 0.050 0.038 0.117 0.136 1.007 
1:1(H:F)  0.421 0.245 0.051 0.038 0.117 0.136 1.008 
5:1 (H:F)  0.421 0.245 0.051 0.038 0.117 0.136 1.009 
SRCD spectra of the FGF-21 alone and in the presence of molar ratios of heparin were 
analyzed using SELCON 3 (Section 2.12 and 5.2).   
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5.4 Discussion 
CD spectra are averaged and deconvoluted into the spectra of the contributing protein 
secondary structures, alpha helixes, beta strands and random coils. The analysis of CD 
spectra is based on the comparison of protein structures against protein databases using 
different analysis methods. Thus, the selection of methods and databases is important for 
understanding the CD spectra.  Several methods (SELCON 3, CDSSTR, CONTIN and K2D) 
and databases (1, 3 and 6) were used for the spectra of FGF-1 and FGF-2, and the results 
were compared with available 3-D structures of these two proteins.  SELCON 3 and database 
3 were chosen, because combinations of all the other methods and databases provided a poor 
match for their crystal and NMR structures. Through SELCON 3 and database 3 worked 
well in this respect, it is still not completely certain if the deconvolution is correct for FGFs 
for which there are no crystal/NMR structures or when FGFs bind heparin.  
A relevant issue is that of solution versus crystal structure (Section 1.5.2). Thus, conflicts 
between the SRCD data and crystal structures may also simply reflect the difference between 
a crystal and a solution structure, which will always be more dynamic. This highlights the 
value of NMR spectra, which should be closer to the CD spectra. 
A final issue is the contribution from the polysaccharide. Heparin and its analogues have a 
CD signal and this is clearly sensitive to the conformation of the sugar chain [121]. However, 
the chromophores in heparin are weaker than those of proteins (c.f., Fig 6A in Section 4.1 
and Fig. 1 in Rudd, et al. 2008 [121]). Therefore, although the present spectra contain 
contributions from both sugar and protein, the latter will account for over 80 %-90 % of the 
signal. 
Though the SRCD data are complex, very clear relationships are apparent where these data 
are considered with those in Chapter 3. Thus, the SRCD results demonstrated that there was 
not a simple trend in the structural changes when more heparin was added to the FGFs (not 
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one direction of change). It is likely that the structural changes depend on the concentration 
of heparin, but the higher concentrations do not necessarily give larger changes in secondary 
structure. The structural changes may be related to the number of binding sites established in 
Chapter 3. When a small amount of heparin is present, most of the heparin will bind to the 
canonical heparin binding sites (HBS-1) since it is of highest affinity, and this might initiate 
a particular set of conformational changes in the FGF ligands. As more heparin is added, the 
canonical heparin binding sites became saturated, then the heparin will start binding the 
lower affinity HBS-2 and HBS-3, producing additional conformational changes. This could 
explain why at different molar ratios of heparin FGFs present different secondary structures, 
and that there was not a single direction for conformational changes linked to heparin 
concentration. For example, FGF-1 (HBS-1, HBS-2 and HBS-3) has very different 
secondary structures at different molar ratios of heparin, while in contrast, FGF-9, which has 
only an enlarged HBS-1, but no independent HBS-2, HBS-3 or HBS-4, has only one trend of 
conformational change: when heparin concentration increases, the protein structure changes 
from α to β. The sulfation patterns of heparin seem also to have an effect on the protein 
conformational change. For example, FGF-7 binding to D2 and D8 showed that different 
sulfation patterns affect the binding differently (Figure 5.1 B). However, at this point there 
is too little information to tell which sulfation played important part in and whether this is 
identified to that found to be primarily responsible for binding, determined by DSF. It is 
possible that not all sulfate groups involved in binding cause substantial conformational 
change in the FGF. Taken together, the SRCD data also showed that there are multiple 
specificities between FGFs and heparin to effect the FGFs' conformational changes when 
forming the binding complexes. 
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Chapter 6 Analysis of individual FGF-2 
molecules bound to heparan sulfate in the 
pericellular matrix 
6.1 Introduction 
FGF-2 mediates its bioactivity by binding to the matricellular and cell surface HS. In the 
pericellular matrix, FGF-2 may interact with HS or bind to FGFR above the plasma 
membrane to form a complex. It is well established that most of the cell bound FGF-2 is 
associated with HS. At any time, only a small proportion of the FGF-2 is associated with a 
ternary signaling complex, with HS and FGFR [48, 122-124]. Until recently there was no 
evidence for how the binding sites of FGF-2 are distributed in the pericellular matrix. 
Immunocytochemical and immunofluorescence measurements just do not have the spatial 
resolution [125].  However, in a recent paper [114] high resolution techniques show that 
these binding sites are not uniformly distributed in the pericellular matrix of Rama 27 
fibroblasts.  Moreover, in the same paper it is suggested that this non-uniform distribution is 
the reason why FGF-2 undergoes different types of motion in the matrix.  One question that 
this work poses is whether the non-random distribution of the binding sites for FGF-2 in the 
pericellular matrix arises, in part, from the “space” taken up by non-FGF binding 
glycosaminoglycans, namely CS and DS. 
To address this question, and as a means of starting to determine what might be the 
specificity and selectivity of the interaction of FGF-2 with endogenous cellular HS, a series 
of experiments were carried out with gold nanoparticle labeled FGF-2 (FGF-2-NP). Using 
this method, FGF-2 was conjugated with Tris-NTA-nanoparticles (Tris-NTA-NPs) at a 
stoichiometry of 1 FGF: 1 nanoparticle, according to a recent published method [106]. Such 
FGF-2-nanoparticles possess similar activity to free FGF-2 [114]. The distribution of FGF-2-
NPs was measured at 2 concentrations (0.55 nM, 2.8 nM) with or without 0.5 mg/mL DP12. 
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Chondroitinase and hyaluronidase were used to remove the CS and HA from the cell 
surfaces.  
6.2 Methods 
6.2.1 Preparation of Tris-NTA gold nanoparticles and FGF2-NP. 
6.2.1.1 Materials: 
1. Modified peptides CVVVT-ol (T-ol is for threoninol) (Anaspec Inc., San Jose, CA): 
working solution: 4 mM in DMSO. 
2. PeGylated alkanethiol SH-C11-EG4-OH (Prochimia Surfaces Sp. Zo.o., Sopot, Poland): 
360 µL methanol was added to the100 mM SH-C11-EG4-OH stock solution (in methanol) to 
make a 10 mM working solution. 
3. Colloidal Gold Nanoparticles (NP) (BritishBiocell (BBInternational Ltd., UK)): diameter 
8.6 nm: stabilized in citrate buffer. 
4. Tris-NTA powder: 10 mM in methanol. 
5. Nanosep centrifugal ultra filtration devices: PALL (PALL Corp., Portsmouth, Hants, UK). 
6. G25 Sephadex superfine (Sigma-Aldrich): 10 mL column. 
7. Tween 20 (Sigma-Aldrich). 
8. 200 ml NaCl. 
9. 250 mM NiSO4.  
10. 10×PBS (a ten-fold concentrated solution of PBS): 8.1 mM NaHPO4, 1.2 mM KH2PO4, 
140 mM NaCl, and 2.7 mM KCl, pH7.4. 
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11. Peptide Biotin-GAAHHHHHH: at 10 mg/mL in PBS (7.24 mM, MW 1380, Sigma-
Aldrich). 
12. Strep-Tactin Sepharose. Binding capacity for biotin> 300 nmoles/mL. 
6.2.1.2 Preparation of 1 mL of mix matrixed NPs 
One hundred µL of ligand mix contained: 35 µL 4 mM CVVVT-ol, 6 µL 10 mM SH-C11-
EG4-OH, 52 µL H2O, 6 µL methanol, 1 µL Tris-NTA were all added together and vortexed. 
The ligand solution was titrated into 900 µL gold nanoparticles and mixed by vortex. Then 
100 µL 10 × PBS was added, mixed by vortexing and left to react on a rotating wheel 
overnight at room temperature. The NPs concentration was calculated using the epsilon 
value of 10 nm gold NP, ε520nm (9.5 × 10
8
) [106].  
6.2.1.3 Preparation of hexa-histidine-Sepharose beads 
Four mL of Strep-Tactin Sepharose was washed with 3×10 ml PBS. Biotinylated 6×His 
peptide (200 µL, 7.4 mM) was added to the Strep-Tactin Sepharose to a final concentration 
of 300 µM. Then 8 mL of PBS with 0.01 % (v/v) Tween was also added and the gel slurry 
incubated on a rotating wheel overnight. After incubation, the resin was loaded into a 10 mL 
plastic column, which was then washed with 5× 10 mL PBS and 2× 10 mL H2O with 0.01 % 
(v/v) Tween. Any free biotin binding sites on the Strep-Tactin Sepharose were blocked by 
adding 5 mL of 1 mM biotin. After that, the resin was washed by 10×10 mL H2O with 0.01 % 
(v/v) Tween and 5×10 mL PBS and then stored in PBS with 0.02 % (w/v) azide at 4oC.  
6.2.1.4 Preparation of Tris-NiNTA–Capped NPs 
Mixed matrix NPs were concentrated with nanosep filters by centrifugation at 7,700 ×g for 7 
min and were then loaded onto a 10 mL Sephadex G25 column, equilibrated in 200 mM 
NaCl. The column was washed with 200 mM NaCl, and the sample of the concentrated NPs 
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applied. Fractions (3 mL) were collected and those corresponding to the excluded volume 
(coloured red due to the absorbance of the nanoparticles) were collected. The excess ligands 
(<1000 Da) eluted at the end of the included volume and so were well separated from the 
nanoparticles. The Tris-NTA groups were loaded with Ni
2+
 by adding 250 mM NiSO4 to the 
nanoparticle containing fractions and incubating for at least 2 h on a rotating wheel. The (v/v) 
ratio of NiSO4: NP was 1:3. 
The nanoparticles were concentrated again using Nanosep filters, which also removed some 
unbounded NiSO4. Then the nanoparticles were applied again to a 10 mL G25 column as 
before and the excluded fraction was collected and buffer exchanged to 1×PBS.  
NPs bearing at least one Tris-Ni-NTA were then purified using His Sepharose. Ten percent 
volume of the hexa-histidine Strep-Tactin Sepharose was added to the nanoparticles and 
placed on a rotating wheel overnight. The Sepharose was then placed in a column and 
washed with 10 volumes of PBS, then the nanoparticles were eluted with 200 mM imidazole 
in PBS and buffer exchanged into H2O using Nanosep filters. 
6.2.1.5 Coupling Histag-FGF to the Tris-Ni-NTA-Capped NPs 
NP with just one Tris-Ni-NTA were concentrated to 178 mM, and mixed with 197 µM His-
tag FGF-2 and left to react on a rotating wheel at 4oC overnight. The reaction mixture was 
then concentrated and buffer exchanged to PBS using Nanosep filters. Excess FGF-2 was 
removed by centrifugation at 10,000 ×g for 7 min. The nanoparticle pellets were resuspended 
in PBS. FGF-2-NP concentration was calculated using the epsilon value of 10 nm NPs, ε520 
nm (9.5×10
8
) [106]. 
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6.2.2 Transmission electron microscopy (TEM) 
6.2.2.1 Production of coated TEM grids 
6.2.2.1.1 Materials:  
Pioloform: 0.3 % (w/v) Pioloform diluted in chloroform 
Grids: 200 mesh (TAAB Laboratories Equipment Ltd., Berks, UK) 
Glass Slides: 1.0 mm × 1.2 mm thick (Agar Scientific, Essex, UK) 
6.2.2.1.2 Pioloform coating grids 
The grids were first washed in ethanol and dried in a dry oven at 40
o
C. The 3 % Pioloform 
(w/v) was placed in a glass dip-mister, which had been first washed with chloroform. The 
cleaned glass slide was dipped into 3 % Pioloform (w/v) and slowly pulled out and dried in 
air Excess film on the dried slide was trimmed to the edge of the glass with a razor blade and 
was then moisturized by breathing on both sides. Then, the coverslip was slowly dipped into 
water so that the film separated from the glass and floated on the water. The dried grids were 
placed onto the floating film and the film full of grids was picked up from the water and 
placed onto a glass slide with a white label on it. The grids were dried for 1-5 days. 
6.2.2.1.3 Carbon coating grids 
The dried grids were carbon coated with a carbon coating machine. 
6.2.2.2 Chondroitinase and Hyaluronidase digestion 
6.2.2.2.1 Chondroitinase digestion 
Chondroitinase (Sigma-Aldrich) (20 mU/40 µL dissolved in water) were diluted 100 fold 
and Chondroitinase buffer (500 mM Tris acetate, pH 8.0) were diluted 5 fold with RM 
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medium and 500 µL of the dilution were added into each well and incubated at 37
o
C for 
overnight. 
6.2.2.2.2 Hyaluronidase digestion 
Hyaluronidase (Sigma-Aldrich) (20 mU/60 µL dissolved in water) was diluted 100-fold into 
cell culture medium and 500 µL of the dilution was added into each well and incubated at 
37
o
C overnight. 
6.2.2.3 Preparation of plasma membrane sheets 
6.2.2.3.1 Materials:  
1. PBS: 8.1 mM Na2HPO4, 1.2 mM KH2PO4, 140 mM NaCl and 2.7 mM KCl, pH 7.4 
2. 10 mg/mL BSA in PBS 
3. Ringer: 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 11 mM glucose, 10 mM 
Hepes, pH 7.4 
4. Reaction buffer: Ringer: 10 mg/ml BSA in PBS (1:9/2:8). 
5. Cells: Rama27 passages 30 to 40 
6. Gold nanoparticles: 10 nm from BBI with a mix matrix ligand shell containing with n=0, 
n=1 or n=1-2 Tris-Ni-NTA per nanoparticle. 
7. KOAc (Potassium acetate buffer): 25 mM Hepes, 115 mM potassium acetate, 2.5 mM 
MgCl2, pH 7.4. 
8. 4 % (w/v) PFA, 0.1 % (v/v) glutaraldehyde.  
9. 2 % (w/v) methylcellulose and 3% (w/v) uranyl acetate were mixed at a ratio of 9:1 (v/v). 
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6.2.2.3.2 Method: 
Cells were grown on 13 mm
2
 coverslips (Section 2.7) until they were 50% confluent and 
then were subjected to digestion with chondroitinase, hyaluronidase or both overnight 
(Section 6.2.2.2). Cells were then incubated in SDM (Section 2.7) for 4 h at 37℃. The 
coverslips with cells were then washed twice with PBS. Samples (200 µL for each) (Tris-
NTA-NPs, 2.8 nM with 0.5 mg/mL DP12, 0.55 nM or 2.8 nM FGF-2-NPs, concentrations 
were calculated as described in Section 6.2.1.5 were added to different wells for 3 min at 
room temperature and then left to incubate for 3 h on ice to prevent receptor-mediated 
endocytosis of the FGF-2. Previous work [122] has shown that on ice FGF-2 binding to cells 
reaches a maximum by 90 min. 
After incubation the cover slips were washed twice with PBS, and then the cells on the 
coverslips were pressed lightly onto two grids, which were placed on a clean filter paper to 
avoid contamination. 
The coverslip was turned over, and KOAc buffer (200 µL) was quickly added around the 
grids to separate them from the coverslip. Then, the grids with membranes were fixed by 
adding 4 % PFA (w/v) and 0.1 % (v/v) glutaraldehyde in KOAc for 10 min. The reaction 
was stopped with 3 × 3 min incubation in 50 mM glycine in PBS. The grids were then 
washed with 5×1 min H2O. The grids were first washed twice by methylcellulose 2 % (w/v) 
and uranyl acetate 3 % (w/v) solution and incubated in this solution for 10 min. 
Grids were picked up separately with loops and the excess solution was dried slowly with a 
piece of filter paper and then they were left dry on the loop for 10 min. Grids were carefully 
removed with tweezers from the loop and placed in an FEI Tecnai G
2
 120 kV transmission 
electron microscope (TEM). 
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6.2.2.4 TEM imaging and data analysis 
At least 24 images were acquired at 26,500 × or 43,000 × magnification. At least 24 
imagines were accounted for each sample (except negative controls). 
The number of NPs was counted manually in each image and used to calculate the number of 
NPs per µm
2
. The mean and SD for each sample were determined and the non-parametric 
Kplmogorov-Smirnov test was used to determine the significance of any differences. 
The backgrounds of single images (750×750 nm
2
) were changed to white with Adobe 
Photoshop and the co-ordinates of dots corresponding to NPs were then calculated by Image 
J and exported. The spatial data were analyzed by an Excel Macro, which implemented 
Ripley's K-function analysis of clustering [114, 126]. The analyzed data were then combined 
and mean values calculated and plotted. 
6.3 Results and discussion: 
To examine the distribution of FGF-2 in the pericellular matrix of Rama 27 cells at the single 
molecule level the growth factor was labeled with a 8.6 nm diameter gold nanoparticle probe 
at a stoichiometry of 1:1 [106, 114] (Section 6.2). The hexa-histidine tag of FGF-2 is on its 
N-terminus, so the Tris-NTA-NP is on the opposite side of the protein to the canonical 
heparin binding site [18] and the FGFR binding sites of FGF-2 [52, 116].  In addition, there 
are natural N-terminal extensions of FGF-2, which do not affect its ability to bind to HS or 
FGFR [48]. Such FGF-2-NPs have been shown to stimulate DNA synthesis and the 
phosphorylation of the adaptor protein FRS2 and p42/44MAPK to the same extent as 
unlabelled FGF-2 [114]. Taken together, these data mean that the FGF-NP will be able to 
interact with its HS co-receptors and FGFR similarly to unlabelled FGF-2. 
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Figure 6.1 Distribution of FGF-2-NP in the pericellular matrix of Rama 27 fibroblasts. 
Two concentrations of FGF-2-NP (0.55 nM and 2.8 nM) were added to living cells and 
incubated for 3 h on ice, then washed and plasma membrane sheets were prepared for TEM 
(Section 6.2.2). Cells incubated with A, 2.8 nM NP-Tris-NTA; B, 2.8 nM FGF-2-NP with 
0.5 mg/ml DP12; C, 550 pM FGF-2-NP; D, 2.8 nM FGF-2-NP.Scale bar is 250 nm. 
A. 2.8 nM NP-Tris-NTA B. 2 .8 nM FGF-2-NP with DP12
C. 0.55 nM FGF-2-NP D. 2.8 nM FGF-2-NP
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A 0.55 nM FGF-2-NP, chondroitinase B 2.8 nM FGF-2-NP, chondroitinase
C 0.55 nM FGF-2-NP, hyaluronidase D 2.8 nM FGF-2-NP, hyaluronidase
E 0.55 nM FGF-2-NP, C+H F 2.8 nM FGF-2-NP, C+H 
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Figure 6.2 Effect of enzyme digestion on the distribution of FGF-2-NP in the 
pericellular matrix of Rama 27 fibroblasts. 
Cells were treated with chondroitinase ABC (C), hyaluronidase (H) or both (C+H) (Section 
6.2.2.2), after which FGF-2-NP (0.55 nM or 2.8 nM) was added and incubated for 3 h on ice 
and then the cells were washed and plasma membrane sheets were prepared for TEM 
(Section 6.2.2). A-C, 0.55 nMFGF-2-NP; C-E, 2.8 nM FGF-2-NP; A, D, Chondroitinase 
digested; B, E Hyaluronidase digested; C, F, cells digested with both chondroitinase ABC 
and hyaluronidase (C+H).  Scale bar is 250 nm. 
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 FGF-2-NP Chondroitinase hyaluronidase Double digest DP12 
0.55 nM (number) 75 80 90 74 - 
2.8 nM (number) 235 164 264 208 0.47 
0.55 nM (P value) 1.87e-5 0.421 0.478 0.94 - 
2.8 nM (P value) 1.87e-5 0.097 0.965 0.562 0 
 
 
N
u
m
b
e
r 
o
f 
N
P/
µ
m
2
FGF2-NPs 0.55 nM 2.8 nM
DP12 - - - - - - - - +
Chondroitinase - + - + - + - + -
hyaluronidases - - + + - - + + -
0
100
200
300
400
500
0
0.5
A 
B 
Hyaluronidase 
Chondroitinase 
C+H 
NPs 
 
 
Hyaluronidase 
Chondroitinase 
NPs 
C+H 
 
 
2.8 nM 
0.55 nM 
  
C 
r (nm) 
L(
r)
-r
 
Analysis of individual FGF-2 molecules bound to heparan sulfate in the pericellular matrix 
 
151 
 
Figure 6.3 Analysis of FGF-2 NP in the pericellular matrix 
Rama 27 cells were grown on glass coverslips, and treated with or without overnight enzyme 
digestions (chondroitinase, hyaluronidase or both), incubated with FGF-2-NPs or FGF-2-
NPs in the presence of 0.5 mg/mL DP12 at two different concentrations (0.55 nM and 2.8 
nM). The coverslips were washed and, after fixing the cells, sheets of plasma membrane and 
associated pericellular matrix were prepared for TEM (Section 6.2.2). Analysis of images of 
TEM of plasma membrane. A, Average number of NPs per µm
2
measured from at least 20 
images (725×725 nm
2
) at two different concentrations with or without digestions or with 0.5 
mg/mL DP12 (mean ± SD).The number of NP/µm
2
 when cells were incubated with 2.8 nM 
FGF-2-NP was 235, 164 following chondroitinase ABC digestion, 264 after hyaluronidase 
digestion, 208 for chondroitinase ABC and hyaluronidase digestion, and 0.47 in the presence 
of DP12.  The number of NP/µm2 when cells were incubated with 0.55 nM FGF-2-NP was 
75, 80 for chondroitinase digestion, 90 for hyaluronidase digestion, and 74 for digestion with 
both enzymes. B, the clustering of FGF-2-NP at two different concentrations (2.8 nM and 
0.55 nM) in the pericellular matrix of cells with or without digestion (chondroitinase, 
hyaluronidase or double digested) was analysed by Ripley's K function (Section 6.2.2.4). A 
value of L(r)-r above the 99 % confidence interval (CI) (black line) indicates significant 
clustering within the defined x-axis radius values (r). C, The non-parametric Kolmogorov-
Smirnov test gave the following P-values: 0.55 nM FGF-2-NP against 2.8 nM, P=1.87 e-5; 
0.55 nM FGF-2-NP against chondroitinase digested, P=0.421; 0.55 nM FGF-2-NP against 
hyaluronidase digested, P=0.478; 0.55 nM FGF-2-NP against double digested, P=0.94; 2.8 
nM FGF-2-NP against chondroitinase digested, P=0.097; 2.8 nM FGF-2-NP against 
hyaluronidase digested, P=0.965; 2.8 nM FGF-2-NP against double digested, P=0.562, 2.8 
nM FGF-2-NP against 2.8 nM FGF-2-NP in present of DP12, P=0.   
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In the pericellular matrix, FGF-2 may interact with HS or bind to the FGFR to form a 
signalling complex. As with most cells, the number of HS binding sites on Rama 27 
fibroblasts has been shown to be ~100- to ~1000-fold greater than the number of FGFR 
binding sites [114, 122].  To highlight that FGF-2-NP is indeed primarily engaged with the 
HS co-receptor on these cells, 0.5 mg/mL DP12 was included in some of the incubations. 
DP12 will compete for binding to endogenous cellular HS, but it will also enable the 
formation of ternary signalling complexes with the FGFR [57, 114]. The results showed that 
only a small number of FGF-2-NP (at the higher concentration 2.8 nM) remained bound to 
the cell in the presence of DP12 (Figures 6.1 and 6.3). By counting the number of NPs on 
the cell membrane, it was found that DP12 caused a~400 fold reduction in the binding of 
FGF-2-NP (Figure 6.3), which agrees with previous studies [114, 122]. The digestions with 
chondroitinase ABC and hyaluronidase also served as controls for the specificity of binding. 
Though hyaluronidase digested cells had a slightly higher number of FGF-2-NP and 
chondroitinase ABC digested cells a slightly lower (for 2.8 nM) number of FGF-2-NP than 
undigested cells, the non-parametric Kolmogorov-Smirnov test demonstrated that these 
differences were not significant (P-values for all digestions> 0.05). Thus, these differences 
are likely to be due to experimental noise. However, there may also be a contribution from 
the cells adjusting to the effect of the digestions, since these were performed on live cells. 
Together with the DP12 competition data, these data indicate that the FGF-2-NPs are indeed 
bound to HS in the pericellular matrix of Rama 27 cells and that other glycosaminoglycans 
did not significantly contribute to this binding. 
The distribution of FGF-2-NPs bound to HS in the pericellular matrix was analyzed by 
Ripley's K-function, which showed that the FGF-2-NP were clustered; that is, their spatial 
distribution was not random (Figure 6.3). At the lower concentration of 0.55 nM FGF-2-NP 
they were found to be clustered at ~100 nm (out of 99 % confidence). This is slightly 
different to that observed previously [114].  However, the line is only just above the 99 % 
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confidence interval, so there is perhaps more uncertainty in the present results and more data 
would have to be acquired to determine if this is a real difference. In cells digested with 
chondroitinase, clustering was more evident and occurred from ~150 nm to 200 nm, whereas 
in hyaluronidase treated cells, FGF-2-NP were clustered at all lengths above 100 nm. 
Surprisingly, digestion of both chondroitinase sulfate and hyaluronic acid resulted in only 
marginal clustering at ~ 80 nm. At the higher concentration of 2.8 nm FGF-2-NP, all samples 
were showed clustering at lengths from ~20 nm (Figure 6.2).  
These results demonstrate that the conjugation of gold nanoparticles to FGF-2 provides a 
highly specific probe to analyze its interactions with HS in the pericellular matrix of cells, 
since most of the FGF-2-NP is bound to HS rather than some other glycosaminoglycan or the 
FGFR. Although FGF-2-NP did not interact with chondroitinase sulfate or hyaluronic acid, 
digestion of these glycoaminoglycans did, under some circumstances, affect the clustering of 
the FGF-2. Thus, at 0.55 nM FGF-2-NP, digestion of these sugars increased the clustering of 
the FGF-2. Though no such effect was observed at 2.8 nM FGF-2-NP, it should be noted that 
at this higher concentration clustering was evident at all lengths above 20 nm for the 
undigested control cells, so differences were unlikely to be observed by this analysis.  
However, the different L(r)-r values found with control and enzyme digested cells indicates 
that there was an effect of enzyme digestion. Clearly some other analysis of clustering and/or 
a different experimental design might reveal more. For example, the digestions were 
performed on live cells. This would allow the cells to adapt their pericellular matrix. 
Digestion on fixed cells may have provided more clear-cut differences. In any event, it 
would seem that the non-FGF-2 binding glycosaminoglycans CS and HA either through their 
interactions with other proteins or simply because they take up a substantial amount of space 
in the pericellular matrix affect the distribution of the binding sites of FGF-2 in HS. These 
binding sites, as has been shown previously [114] are not distributed randomly. The present 
results, therefore, raise the possibility that the distribution of the free binding sites for FGF-2 
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in the pericellular matrix might be controlled, at least to an extent, by the level and structures 
of glycosaminoglycans that do not bind FGF-2. 
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Chapter 7 General discussion and conclusion 
7.1 Discussion 
The necessity for HS to bind FGFs to form the FGF-receptor complexes led us to 
study the binding of the HS to FGFs. The interaction of FGFs with HS is far from 
unique; at least 435 heparin binding proteins are encoded in the human genome and 
they are clearly key regulators of cell communication [89, 90]. Thus, the question of 
the binding specificities between HS and these proteins becomes important. There 
are two positions regarding specificity. One is that there are clear specificities for the 
heparin-proteins interactions, whereas the other is that there is little specificity 
beyond the size of oligosaccharide and that the binding is entirely charge-driven 
(Section 1.11). With 22 FGFs members, the evolutionary relationships between the 
different members and the association of heparin selectivity of these FGFs is an 
interesting platform to tackle the question of specificity. Thus, in this thesis, FGFs 
from different subfamilies were used so that the evolutionary relationships of this 
protein family could be exploited in the interpretation of the results. Six FGFs (FGF-
1, FGF-2, FGF-7, FGF-9, FGF-18 and FGF-21) from 5 different sub-families were 
produced as recombinant proteins and their interactions with a library of heparin 
sugars and cellular HS were measured by several different methods. 
In Chapter 4, four different approaches were used to determine what level of binding 
specificity might exist. First, the differences of binding kinetics of four FGFs (FGF-1, 
FGF-7, FGF-9 and FGF-18) to a model, heparin octasaccharide (DP8) showed there 
are binding specificities with respect to the binding parameters, which supports the 
idea that the HBS-1 of different FGFs possess different kinetics and affinities for 
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heparin, e.g., FGF-7 has very different KD when binding to DP8 compared to FGF-1 
and FGF-2. Ionic bonding dominates kinetics, just as it does the qualitative 
measurements that use the concentration of NaCl required to dissociate sugar-protein 
complex as a proxy for affinity. However, DSF and SRCD, which are not necessarily 
dominated by ionic interactions, demonstrated that there was a lot of conformational 
change in FGFs when they bound to heparin (Section 4.2). Presumably, this is why 
ionic binding was found to only account for 30 % of ∆G of the FGF-2: heparin 
interaction and other 70 % was from nonionic interactions, such as hydrogen bonding 
and van der Waals packing [88]. 
The HBSs of the FGFs were found to differ. By comparing biosensor, Protect and 
Label and the DSF data, we can clearly see the relationships of binding activities of 
different HBSs. In a previous study that used peptides, FGF-2 HBS-1 (peptide 127-
140) and HBS-2 (peptide 117-126) binding to heparin was measured in an optical 
biosensor; the KD of the peptide corresponding to HBS-1 was 30±4 µM, and that of 
the peptide corresponding to HBS-2 was 120±50 µM. In contrast the KD FGF-2 
binding to heparin, which can only measure the highest affinity site (HBS-1) was 
84±55 nM [115]. However, peptides do not have restricted conformations, so the 
peptide HBS-1 KD (30±4 µM), which is of the order of 1000-fold lower affinity than 
when in the context of the protein is reasonable. Thus, the binding affinity of HBS-2 
may also be 100- to 1000-fold higher than when determined with a peptide: 1.0 to 0.1 
µM in the FGF-2 protein. The ITC determination of the KD of FGF-2 for heparin in 
0.1 M NaCl found a value of 0.47 µM [88]. ITC requires saturation of all binding 
sites and the experiment was conducted at a lower concentration of electrolytes than 
PBS. Thus, this is consistent with an average of HBS-1, HBS-2 and HBS-3. 
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Moreover the DSF data showed that the thermostabilizing effect of FGF-2 binding to 
heparin reached the highest level at 25 µM heparin (Figure 4.3). Assuming that 
thermostabilization of FGF-2 is contributed to by all three HBSs, together these data 
suggest that FGF-2 can indeed bind to heparin via all three sites. 
The FGF-1 biosensor data showed that the affinity of FGF-1 for DP8 (KD=60±6.2 
nM) was similar to that of FGF-2. Interestingly, the FGF-1 DSF data showed that the 
thermostabilization of FGF-1 by heparin had not reached at a maximum at 500 µM, 
the highest concentration of heparin used (Figure 4.2). This is consistent with the 
FGF-1 binding to heparin by all three of its HBSs. Similarly FGF-18’s 
thermostabilization by heparin was still rising at 500 µM, while the KD of FGF-18 
for DP8 (reflecting binding by HBS-1) was 38±12 nM, which also indicated that the 
binding between FGF-18 and heparin relates to both of its HBSs. 
Although the thermostabilizing effect of heparin binding on FGF-7 reached a 
maximum at 5 µM, the KD of FGF-7 for DP8 measured in the biosensor was 
KD=290±49 nM (Table 3 in Section 4.2). The 17-fold difference may be due to 
FGF-7 binding to heparin through HBS-1, HBS-2, and maybe also HBS-4, and/or the 
protein accommodating the sugar in different orientations across its ‘T’ shaped 
binding site at different concentrations. In contrast, there was no large difference 
between the affinity of FGF-9 for DP8 measured in a biosensor, KD=620±340, and 
the concentration of heparin required to elicit maximal thermostabilization (1.25 µM). 
Since at KD half the binding sites are occupied, these data are consistent with FGF-9 
possessing a single HBS. The above highlights the value of using different 
approaches to analyze a molecular interaction. Consistencies and apparent 
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discrepancies appear, which, when considered with what a particulate technique 
actually measures, allows important conclusions to be drawn. 
The DSF experiments gave a view of different sugars binding to these FGFs. The 
concentration of sugars used here (5 µM) would probably not be too sensitive to 
multiple HBSs, though there might be some contribution from HBS-2. The better 
binding of heparin/HS compared to HA, CS and DS and selective binding of 
heparins of different lengths and sulfation patterns demonstrates that the interactions 
are not simply based on ion-exchange. The selectivity of sugar structures was 
separable by PCA, with the results clearly showing that there were specificities when 
different proteins bound to heparin. However, there is clearly no simple and absolute 
specificity. This is reasonable, since such specificity is the exception rather than the 
rule. For example, FGF ligands have clear selectivity for different FGFRs, but except 
for FGF-7 this is never one to one (Table 1.1). Thus, more useful is the idea of a 
consensus site used to describe the DNA sequences bound by transcription factors. 
Departures from consensus often reflect the occunence of a higher degree of 
regulation rather than binding that is not functionally significant.    
An analysis of the HBS and FGFR binding sites reveals some interesting features. 
The HBS-3 of FGF-1, FGF-2, FGF-7 (predicted) overlapped with the FGFR binding 
sites, and in FGF-1 and FGF-2 part of HBS-2 also overlapped with their FGFR 
binding sites. Thus, the HBS-3 and part of HBS-2 in some instances may be involved 
in the transport of the FGF on the cell surfaces, but not in the formation of the FGFR 
complex. Indeed their secondary HBS may negatively regulate this, which may 
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account for the previous identification of HS structures that bind FGF-2, but do not 
allow the activation of mitogenic signaling [85, 96, 127]. 
However, the above is all with model sugars and purified molecules. In reality the S 
and SAS domains of HS (Section 1.6.3, [32]) are less sulfated than heparin and in 
vivo already associated with endogenous proteins. So what FGF will bind in a cell 
may be rather different. Some S and SAS will not be free and/or require a 
displacement reaction, others may be forced into favorable or unfavorable 
conformations due to the binding of endogenous proteins to the opposing face of the 
sugar. The preliminary work in Chapter 6 demonstrates that it will be possible to gain 
some insights into the interactions of FGFs will real HS in vivo. 
7.2 Future work 
It is clear from this study that there are binding specificities between heparin and 
FGFs, alongside subfamily similarities, which are related to the evolution of FGFs, 
however, the overall picture is far from complete. First, only one representative 
ligand in the FGF-7, FGF-8 and FGF-9 sub-families, and no member of the FGF-4 
sub-family was investigated. The hypothesis that HBS and specificity are conserved 
within subfamilies and varies more between these (Section 4.2) needs formal 
evidence. Ideally the entire set of heparin binding FGF ligands needs to be produced 
and by using similar methods to those in this study understand the differences and 
similarities of the sub-family members in their binding to heparin.  
Despite differences between HS or a cell and pure sugar, the intrinsic specificities 
and preferences of a FGF-sugar interaction in vitro should be reflected in vivo and so 
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determine FGF function. Duchesne et al. 2012 [114] used FGF-2 to predict that the 
transport of heparin binding proteins in extracellular matrix is simply due to cycles of 
association and dissociation from cellular HS. If this is true, then for HS on a given 
cell, two FGFs with different heparin specificities and binding kinetics should exhibit 
different distributions and transport parameters. The original work was done with 
FGF-2, which has a KD ~10
-8
 M and a preference for sulfation patterns of 2S and NS 
[92-95, 102] (Section 4.3). The most different FGFs of the four available compared 
to FGF-2 are FGF-7 and FGF-9; the binding affinity of DP8 to FGF-7 (KD= 290±49 
nM) is about 10-fold lower and for FGF-9 (KD= 620±340 nM) around 50-fold lower 
than FGF-2 (KD= 11±2 nM) (Table 3 in Section 4.2) [57]. Moreover, their sulfation 
patterns preferences are different, both FGF-7 and FGF-9 need 6S and NS more than 
2S (Figure 8 in Section 4.2). Therefore, NP conjugated FGF-7 and FGF-9 would 
provide well characterized tools to test this hypothesis. Such work would also pave 
the way for the deployment of nanoparticle probes as a means to analyze the binding 
of FGFs to HS in cells, rather than to purified sugars. 
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Supplemental data 
Papers and manuscripts 
Contributions to work 
Paper1 
Uniewicz,  K.A., Ori, A., Xu, R., Ahmed, Y., Fernig, D.G. and Yates, E.A. (2010). 
Differential Scanning Fluorimetry measurement of protein stability changes upon 
binding to glycosaminoglycans: a rapid screening test for binding specificity.  Anal. 
Chem. 82: 3796-3802. 
Produced FGF-18 protein and contributed to the development of the DSF assay. 
Paper 2 
Rudd, T.R., Uniewicz,  K.A., Ori, A., Guimond, S.E., Skidmore, M.A., Gaudesi, D., 
Xu, R., Turnbull, J.E., Guerrini, M., Torri, G., Siligardi, G., Wilkinson, M.C., Fernig, 
D.G. and Yates, E.A. (2010). Comparable stabilisation, structural changes and 
activities can be induced in FGF by a variety of HS and non-GAG analogues: 
Implications for sequence-activity relationships. Org. Biomol. Chem. 8: 5390-5397  
Produced FGF proteins and contributed to data acquisition at synchrotron. 
Paper 3 
Thompson, S.M., Connell, M.G., van Kuppevelt,,T.H., Xu, R., Turnbull, J.E., Losty, 
P.D., Fernig, D.G. and Jesudason, E.C. (2011). Structure and epitope distribution of 
heparan sulfate is disrupted in experimental lung hypoplasia: a glycobiological 
epigenetic cause for malformation?  BMC Dev. Biol. 11:38. 
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Produced FGF-9 protein used to demonstrate specificity and biological significance 
of epitopes recognized by HS antibodies. 
Paper 4 
Xu, R., Ori, A., Rudd, T.R., Uniewicz, K.A.,Ahmed, Y.A., Guimond, S.E., Skidmore, 
M.A., Siligardi, G., Yates, E.A. and Fernig, D.G. (2012). Diversification of the 
structural determinants of fibroblast growth factor-heparin interactions; implications 
for binding specificity. J. Biol. Chem. 287(47):40061-40073. 
Made FGF proteins, performed the experiments and drafted the entire manuscript.  
other co-authors supplied sugars, led the development of DSF, helped with PCA and 
with acquisition of spectra on the SRCD beamline. 
Paper 5 
Ruoyan Xu, Timothy R. Rudd, Ashley J Hughes, Giuliano Siligardi, David G. 
Fernig and Edwin A. Yates. (2012). Analysis of the FGFR Signalling Network with 
Heparin as Co-Receptor: Evidence for the expansion of the core FGFR signalling 
network. Submitted to FEBJ, December 2012. 
Made FGF proteins, acquired spectra, interpreted these and drafted manuscript. 
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